[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 254
1. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D: Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol; 2008 Jun 7;14(21):3374-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver-related autoantibodies are crucial for the correct diagnosis and classification of autoimmune liver diseases (AiLD), namely autoimmune hepatitis types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis variants in adults and children.
  • AIH-2 is specified by antibody to liver kidney microsomal antigen type-1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1).
  • SMA, ANA and anti-LKM antibodies can be present in de-novo AIH following liver transplantation.
  • PBC is specified by antimitochondrial antibodies (AMA) reacting with enzymes of the 2-oxo-acid dehydrogenase complexes (chiefly pyruvate dehydrogenase complex E2 subunit) and disease-specific ANA mainly reacting with nuclear pore gp210 and nuclear body sp100.
  • Sclerosing cholangitis presents as at least two variants, first the classical primary sclerosing cholangitis (PSC) mostly affecting adult men wherein the only (and non-specific) reactivity is an atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA), also termed perinuclear anti-neutrophil nuclear antibodies (p-ANNA) and second the childhood disease called autoimmune sclerosing cholangitis (ASC) with serological features resembling those of type 1 AIH.
  • [MeSH-major] Autoantibodies / blood. Autoantigens / immunology. Cholangitis, Sclerosing / diagnosis. Hepatitis, Autoimmune / diagnosis. Liver Cirrhosis, Biliary / diagnosis. Serologic Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1969 May;4(5):511-25 [5787343.001]
  • [Cites] Immunology. 1969 Aug;17(2):281-93 [5804537.001]
  • [Cites] Am J Pathol. 1973 Sep;72(3):473-88 [4125700.001]
  • [Cites] Clin Exp Immunol. 1973 Nov;15(3):331-44 [4587503.001]
  • [Cites] Br Med J. 1974 Apr 13;2(5910):80-4 [4596402.001]
  • [Cites] Immunology. 1974 Mar;26(3):589-601 [4604207.001]
  • [Cites] Clin Exp Immunol. 1976 May;24(2):266-72 [945140.001]
  • [Cites] J Clin Pathol. 1976 May;29(5):403-10 [777046.001]
  • [Cites] Clin Exp Immunol. 1979 Dec;38(3):621-8 [93995.001]
  • [Cites] Clin Exp Immunol. 1983 Oct;54(1):232-8 [6352105.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):347-54 [6199139.001]
  • [Cites] Lancet. 1984 Oct 27;2(8409):954-6 [6149344.001]
  • [Cites] Lancet. 1985 Feb 23;1(8426):425-9 [2857806.001]
  • [Cites] Lancet. 1987 Feb 7;1(8528):292-4 [2880112.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3525-31 [3571977.001]
  • [Cites] Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):614 [3653625.001]
  • [Cites] Hepatology. 1987 Nov-Dec;7(6):1333-9 [3679093.001]
  • [Cites] Liver. 1987 Dec;7(6):307-15 [3437792.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1067-70 [2896910.001]
  • [Cites] J Exp Med. 1988 Aug 1;168(2):801-6 [2842431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256-60 [3186722.001]
  • [Cites] Hepatology. 2001 Mar;33(3):591-6 [11230739.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):366-72 [11322196.001]
  • [Cites] Liver. 2001 Aug;21(4):225-32 [11454184.001]
  • [Cites] Hepatology. 2001 Sep;34(3):494-501 [11526534.001]
  • [Cites] Clin Exp Immunol. 2001 Oct;126(1):37-46 [11678897.001]
  • [Cites] Liver Int. 2006 Aug;26(6):633-5 [16842317.001]
  • [Cites] Clin Chim Acta. 2006 Nov;373(1-2):183-4; author reply 185 [16714006.001]
  • [Cites] Dig Liver Dis. 2006 Oct;38(10):781-2; author reply 782-3 [16870516.001]
  • [Cites] Hepatology. 2007 Jan;45(1):118-27 [17187436.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):107-8 [17213359.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2731-6 [17227520.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):454-5 [17295788.001]
  • [Cites] Hepatology. 2007 Mar;45(3):659-65 [17326160.001]
  • [Cites] PLoS Biol. 2007 Jan;5(1):e4 [17194211.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jul;77(1):155-6 [17118481.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1131-2 [17489791.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):129-39 [17520513.001]
  • [Cites] Lancet. 1965 Oct 30;2(7418):878-9 [4158243.001]
  • [Cites] Gastroenterology. 1966 Oct;51(4):499-505 [5332194.001]
  • [Cites] J Exp Med. 1967 Aug 1;126(2):277-90 [4165742.001]
  • [Cites] Br J Exp Pathol. 1969 Apr;50(2):200-8 [5772074.001]
  • [Cites] J Autoimmun. 2004 Jun;22(4):353-62 [15120760.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):239-50 [16143941.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):298-310 [16143945.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1261-73 [16177252.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):280-4 [16505279.001]
  • [Cites] Hepatology. 2006 May;43(5):1135-44 [16628641.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):140-51 [17520514.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):161-72 [17520516.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1583; author reply 1583-4 [17538935.001]
  • [Cites] J Clin Immunol. 2007 Jul;27(4):378-87 [17514501.001]
  • [Cites] J Clin Lab Anal. 2007;21(4):227-31 [17621358.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:519-30 [17785341.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1226-31 [17919234.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1662-6 [3192182.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1066-72 [2466049.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1967-73 [2347920.001]
  • [Cites] Hepatology. 1990 Jul;12(1):127-32 [2373473.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1290-5 [1397887.001]
  • [Cites] Hepatology. 1992 Oct;16(4):892-8 [1398495.001]
  • [Cites] Hepatology. 1993 Mar;17(3):411-7 [8444414.001]
  • [Cites] J Immunol Methods. 1993 Feb 26;159(1-2):1-16 [8445241.001]
  • [Cites] Clin Exp Immunol. 1993 May;92(2):308-16 [7683589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9 [12832623.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):860-3 [14568272.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1250-7 [14578864.001]
  • [Cites] Clin Liver Dis. 2003 Nov;7(4):759-77, vi [14594130.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1476-9 [14598264.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):31-9 [14672611.001]
  • [Cites] Dig Liver Dis. 2003 Nov;35(11):801-5 [14674671.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2374-81 [14677180.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):682-3; author reply 683-4 [14981048.001]
  • [Cites] Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):83-92 [15000871.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):763-4; author reply 765 [15089915.001]
  • [Cites] Hepatology. 1997 Oct;26(4):1054-66 [9328334.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):324-8 [9453493.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):409-13 [9482295.001]
  • [Cites] Gut. 1998 May;42(5):721-6 [9659171.001]
  • [Cites] Hepatology. 1998 Aug;28(2):332-40 [9695994.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):643-9 [10029623.001]
  • [Cites] Ann Clin Biochem. 1999 Mar;36 ( Pt 2):189-95 [10370735.001]
  • [Cites] Experientia. 1954 Jun 15;10(6):252-3 [13183062.001]
  • [Cites] Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):789-94 [13204357.001]
  • [Cites] Lancet. 1956 Dec 29;271(6957):1323-6 [13386250.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1436-42 [17657817.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):105-10 [18176872.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):71-8 [9089912.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):79-90 [9089913.001]
  • [Cites] Hepatology. 1997 May;25(5):1090-5 [9141422.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1396-402 [9210629.001]
  • [Cites] Hepatology. 1997 Sep;26(3):567-72 [9303484.001]
  • [Cites] Hepatology. 2008 Mar;47(3):1096-7; author reply 1097 [18306217.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1948 Jan 21;23(2):25-8 [18921142.001]
  • [Cites] Hepatology. 1993 Jul;18(1):1-9 [8325600.001]
  • [Cites] J Hepatol. 1993 Aug;19(1):55-63 [8301043.001]
  • [Cites] J Clin Immunol. 1994 Jan;14(1):14-9 [8132733.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):94-9 [8033426.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1159-66 [7698584.001]
  • [Cites] Biochem Mol Biol Int. 1995 Mar;35(3):473-85 [7773184.001]
  • [Cites] Gut. 1995 May;36(5):749-54 [7797126.001]
  • [Cites] Gut. 1995 Sep;37(3):406-12 [7590439.001]
  • [Cites] J Immunol Methods. 1995 Dec 1;187(2):259-64 [7499885.001]
  • [Cites] Hepatology. 1996 Jul;24(1):97-103 [8707289.001]
  • [Cites] Dig Dis Sci. 1996 Sep;41(9):1733-40 [8794787.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1068-73 [8903377.001]
  • [Cites] Hepatology. 1997 Jan;25(1):6-11 [8985257.001]
  • [Cites] Hepatology. 1997 Mar;25(3):541-7 [9049195.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):61-9 [9089911.001]
  • [Cites] J Hepatol. 1999 Oct;31(4):635-40 [10551386.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3447-8 [11774973.001]
  • [Cites] J Hepatol. 2002 Jan;36(1):14-21 [11804659.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):68-74 [11824974.001]
  • [Cites] Hepatology. 2002 Mar;35(3):658-64 [11870381.001]
  • [Cites] J Clin Lab Anal. 2002;16(4):194-201 [12112392.001]
  • [Cites] Gut. 2002 Aug;51(2):259-64 [12117891.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):906-9 [12461054.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1481-9 [12538711.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):241-3 [12591035.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):431-7 [12591064.001]
  • [Cites] Clin Chem. 2003 Apr;49(4):634-43 [12651817.001]
  • [Cites] J Autoimmun. 2003 May;20(3):247-54 [12753810.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):475-83 [12765472.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):485-92 [12765473.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):515-9 [12765477.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):545-50 [12765481.001]
  • [Cites] Arthritis Res Ther. 2003;5(4):192-201 [12823850.001]
  • [Cites] N Engl J Med. 1958 Jan 23;258(4):185-8 [13493762.001]
  • [Cites] Proc Soc Exp Biol Med. 1957 Dec;96(3):575-9 [13505796.001]
  • [Cites] Lancet. 1959 Jan 10;1(7063):65-9 [13621639.001]
  • [Cites] Cancer Res. 1955 Oct;15(9):598-602 [13261081.001]
  • [Cites] J Clin Invest. 1959 Nov;38:2059-72 [14402750.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1116-22 [15625657.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):508-10 [15712071.001]
  • [Cites] Hepatology. 2005 Mar;41(3):609-16 [15726652.001]
  • [Cites] Hepatology. 2005 Aug;42(2):458-65 [16025495.001]
  • [Cites] Scand J Gastroenterol. 2004 Apr;39(4):405-6; author reply 407 [15125479.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1505; author reply 1505-6 [15156495.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):31-7 [15246204.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):677-83 [15464251.001]
  • [Cites] Scand J Gastroenterol. 2004 Oct;39(10):981-7 [15513338.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1510-5 [10801173.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):310-22 [10930366.001]
  • [Cites] Dig Liver Dis. 2000 Jun-Jul;32(5):440-6 [11030191.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3238-41 [11095348.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):239-49 [11208733.001]
  • [Cites] Hepatology. 2001 Mar;33(3):544-53 [11230733.001]
  • (PMID = 18528935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Reagent Kits, Diagnostic
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2716592
  •  go-up   go-down


2. Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P: Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol; 2009 May;33(5):682-90
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.
  • Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association with t(5;9)(q33;q22) involving ITK and SYK has been suggested.
  • However, the clinicopathologic aspects of PTCL-F are poorly described and the normal cell counterpart of this subgroup of lymphoma is still unknown.
  • Patients with clinical data available had multiple lymphadenopathies (25/28, 89%), stage III to IV diseases (17/26, 65%), B symptoms (7/27, 26%), and skin lesions (6/23, 26%).
  • Three patients with sequential biopsies disclosed clinical and histopathologic features of angioimmunoblastic T-cell lymphoma at initial presentation.
  • Our results show that this rare form of PTCL-F (1) has an immunophenotype indicative of derivation from TFH cells, (2) is associated with t(5;9) in a proportion of cases, and (3) shows some overlapping features with angioimmunoblastic T-cell lymphoma, raising the question of a possible relationship.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Follicular / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD4 / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Biopsy. Chemokine CXCL13 / analysis. Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 9. DNA-Binding Proteins / analysis. Europe. Gene Expression Regulation, Neoplastic. Gene Rearrangement, T-Lymphocyte. Genotype. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Inducible T-Cell Co-Stimulator Protein. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Phenotype. Programmed Cell Death 1 Receptor. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295409.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4838638
  •  go-up   go-down


3. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • It is associated with various hematologic diseases.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A CT scan of the abdomen revealed marked hepatosplenomegaly and small multiple lymphadenopathies.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


Advertisement
4. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica; 2007 Aug;92(8):1059-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: In the present paper we report that SAP, an intracytoplasmic molecule that is involved in cell signaling, is an immunohistologic marker for germinal center T cells in paraffin-embedded tissue.
  • We document its expression, and also that of PD-1 (another recently described marker of germinal center T cells to which a new antibody has been raised), in normal and neoplastic lymphoid tissue to evaluate the suggestion that helper T cells within the germinal centers of human lymphoid tissue are the cell of origin of angioimmunoblastic T-cell lymphoma (AITL), and to assess the diagnostic value of these two markers.
  • DESIGN AND METHODS: Expression of SAP and PD-1 was investigated by immunohistochemistry in paraffin-embedded tissue sections and in cell lines.
  • Western blotting was performed on cell lines, and antibody specificity was confirmed by immunostaining of transfected cells.
  • RESULTS Screening on more than 500 lymphoma biopsies showed that 95% (40/42) of cases of AITL expressed at least one of these markers.
  • However, PD-1 and SAP were also found in a minority of cases of peripheral T-cell lymphoma other than AITL, in contrast to a report that the former marker is specific for AITL.
  • This observation raises the possibility that such non-angioimmunoblastic cases may be related to germinal center helper T cells.
  • They may also prove of value in the diagnosis of this disease since a negative reaction was rarely observed in this disorder.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antigens, CD / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Intracellular Signaling Peptides and Proteins / analysis. Lymphoma, T-Cell / pathology. Neoplasm Proteins / analysis. T-Lymphocytes / chemistry
  • [MeSH-minor] Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphocytes, Tumor-Infiltrating / chemistry. Lymphocytes, Tumor-Infiltrating / pathology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / pathology. Palatine Tonsil / pathology. Programmed Cell Death 1 Receptor. Spleen / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / SH2D1A protein, human
  •  go-up   go-down


5. Yamagata T, Okamoto Y, Yamagata Y, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M: Angioimmunoblastic lymphadenopathy with dysproteinaemia accompanied by pleural effusion. Respirology; 2005 Jan;10(1):124-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic lymphadenopathy with dysproteinaemia accompanied by pleural effusion.
  • Angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) is a rare lymphoproliferative disorder characterized by systemic lymphadenopathy, hepatosplenomegaly, loss of body weight, fever, skin eruption, and polyclonal hypergammaglobulinaemia.
  • Two cases of AILD accompanied by pleural effusion are reported here.
  • Cytologically, atypical plasma cells, and T-cell predominant lymphocytes were also present.
  • These findings are likely to be characteristic of pleural effusions associated with AILD and may prove to be a useful marker for diagnosis.
  • [MeSH-major] Hypergammaglobulinemia / complications. Immunoblastic Lymphadenopathy / complications. Pleural Effusion / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691251.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Receptors, Interleukin-2
  •  go-up   go-down


6. Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, Miyake T, Tanaka J, Nabika T, Ishikura H: Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop; 2010;50(1):59-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma.
  • On rare occasions, secondary Epstein-Barr virus (EBV)-associated B cell lymphoma can develop in a patient with angioimmunoblastic T-cell lymphoma (AITL).
  • We report a case of a 66-year-old Japanese woman who developed diffuse large B-cell lymphoma (DLBCL) in her small intestine after chemotherapy for AITL.
  • In situ hybridization for EBV-encoded RNA revealed positivity in the lymphoma cells.
  • The lymph nodes diagnosed as AITL were negative for EBV infection and there was no coexistence of B cell neoplasms in them.
  • We thought small bowel perforation in this case was caused by EBV-associated B cell lymphoma secondary to AITL.
  • Our case showed a remarkable deficiency of cellular immunity after chemotherapy, which we postulate was related to the cause of occurrence of B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505277.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Ren YL, Hong L, Nong L, Zhang S, Li T: [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):352-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas].
  • OBJECTIVE: To evaluate angioimmunoblastic T-cell lymphoma(AITL) completely, we gave injdepth investigation of histopathological features, specific immunochemical markers, antigen receptor gene rearrangements and in situ hybridization for Epstein-Barr virus (EBV).
  • Polymerase chain reaction for immunoglobulin heavy chain (IgH) and T cell receptor gamma (TCRgamma) rearrangements and in situ hybridization for Epstein-Barr virus encoded RNA (EBER-1) were performed.
  • CD21 expression exihibited extrafollicular expansion of follicular dendritic cell meshworks in 11 cases (73.3%), partially with a tendency of perivascular distribution.
  • Among the four cases with large B cell proliferation, three were EBV-positive.
  • Only when we recognize such diversity, can we reasonably apply and properly evaluate immunochemical markers and molecular techniques, and thus give a correct diagnosis.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677379.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


8. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • METHODS: We retrospectively reviewed our institutional experience with the flow cytometric features of 16 cases of AILT.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


9. Willenbrock K, Renné C, Gaulard P, Hansmann ML: In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch; 2005 Jan;446(1):15-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study.
  • The significance of T-cell proliferations in angioimmunoblastic lymphoma (AILD) is still enigmatic.
  • Although classified as a malignant T-cell lymphoma in the World Health Organisation lymphoma classification, some cases of AILD lack dominant T-cell clones.
  • In a previous study, based on single-cell polymerase chain reaction (PCR), we obtained similar results as studies of AILD using Southern blot or conventional PCR: some cases of AILD contained large T-cell clones, and, in other cases, T-cell clones were undetectable.
  • As in single-cell studies, only a limited number of cells could be investigated; thus, we wanted to gain more insight into the amount and distribution of tumour cells.
  • By applying triple immunofluorescent staining with antibodies directed against T-cell receptor Vbeta-family-specific epitopes, we investigated T-cell populations in AILD and their localisation in the tissue in relation to B cells (CD20) and follicular dendritic cells (CD21).
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphoma, T-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15480765.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Complement 3d
  •  go-up   go-down


10. Yee SB, Bourdi M, Masson MJ, Pohl LR: Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol; 2007 May;20(5):734-44
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.
  • Recent evidence suggests that a deficiency in one or more hepatoprotective regulatory mechanisms may contribute to determining susceptibility in drug-induced liver disease.
  • In the present study, we investigated the role of interleukin (IL)-13 in acetaminophen (APAP)-induced liver disease (AILD).
  • Following APAP (200 mg/kg) administration to male C57BL/6 wild-type (WT) mice, hepatotoxicity developed up to 24 h post-APAP, with a concomitant increase in serum IL-13 concentration.
  • No difference was observed in either overall APAP-protein adduct formation or liver glutathione levels between KO and WT mice following APAP administration, suggesting that the increased susceptibility of IL-13 KO mice to AILD was not due to enhanced APAP bioactivation but rather injurious downstream events.
  • In this regard, multiplex antibody arrays were used to identify potential IL-13-regulated biomarkers, including various cytokines and chemokines, as well as nitric oxide (NO), associated with AILD that were present at higher concentrations in the sera of APAP-treated IL-13 KO mice than in WT mice.
  • Subsequent inhibition studies determined interferon-gamma, NO, neutrophils, natural killer cells, and natural killer cells with T-cell receptors had pathologic roles in AILD in IL-13 KO mice.
  • Taken together, these results suggest that IL-13 is a critical hepatoprotective factor modulating the susceptibility to AILD and may provide hepatoprotection, in part, by down-regulating protoxicant factors and cells associated with the innate immune system.
  • [MeSH-major] Acetaminophen / toxicity. Analgesics, Non-Narcotic / toxicity. Drug-Induced Liver Injury / prevention & control. Interleukin-13 / blood
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Antibodies, Blocking / pharmacology. Biomarkers / blood. Disease Models, Animal. Drug Synergism. Gene Silencing. Glutathione / metabolism. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Neutrophils / drug effects. Neutrophils / metabolism. Neutrophils / pathology


11. Saito M, Fukuda T, Shiohara T, Homori M: Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjögren's syndrome. Clin Exp Rheumatol; 2005 Nov-Dec;23(6):888-90
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjögren's syndrome.
  • An increased risk of developing lymphoma has been indicated in Sjögren's syndrome (SS), and the lymphomas in SS are usually B-cell type in origin.
  • Interestingly, despite the rather low frequency of T-cell lymphoma in SS, angioimmunoblastic T-cell lymphoma (AILD) constitute the majority of T-cell lymphomas associated with SS.
  • To the best of our knowledge, including our case, at least 11 out of 23 (48%) cases of T-cell lymphoma reported in association with SS, were AILD.
  • The fact that the development of B-cell lymphoma in SS is much more frequent than that of T-cell lymphoma, might be explained by differences in the situation between B and T cells, although the exact mechanism still remains uncertain.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Sjogren's Syndrome / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396711.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Mackay IR: Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: Unfinished business. Hepatol Res; 2007 Oct;37 Suppl 3:S357-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: Unfinished business.
  • Autoimmune liver diseases (AILD) including autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) have attracted much attention since their discovery 50 years ago, but there remain items of unfinished business.
  • These relate to disease susceptibility including genetic influences (HLA and non-HLA genes, genes associated with female predisposition, and others) and environmental influences (infections, chemicals, xenobiotics and medications).
  • Deeper analysis of T-lymphocyte function in AILD should reveal relative contributions of eachof the multiple subsets of T cells now being defined in studies on laboratory animals, CD4(+), CD8(+), Th1, Th2, Th17, memory subsets and regulatory subsets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931187.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Welch KD, Reilly TP, Bourdi M, Hays T, Pise-Masison CA, Radonovich MF, Brady JN, Dix DJ, Pohl LR: Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol; 2006 Feb;19(2):223-33
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice.
  • Drug-induced liver disease (DILD) continues to cause significant morbidity and mortality and impair new drug development.
  • Mounting evidence suggests that DILD is a complex, multifactorial disease in which no one factor is likely to be an absolute indicator of susceptibility.
  • As an approach to better understand the multifactorial basis of DILD, we recently compared the hepatic proteomes of mice that were resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD) wherein we identified potential risk factors and mechanistic pathways responsible for DILD.
  • In this study, we have uncovered additional potential risk factors by comparing hepatic mRNA expression profiles of the same two strains of mice with that of SJLxB6-F1 hybrid (F1) mice, which were found to be of intermediate susceptibility to AILD.
  • One of these genes encoded for heat shock protein (HSP) 70 whose relative protein expression among the three strains of mice was found to parallel that of their mRNA levels, suggesting that this protein had a protective role against AILD.
  • However, there was no difference in the susceptibility of HSP70 knockout (KO) mice to AILD as compared to wild-type (WT) mice.
  • In support of this hypothesis, OPN KO mice were found to be more resistant to AILD than WT mice.
  • [MeSH-major] Acetaminophen / toxicity. Drug-Induced Liver Injury. Genetic Predisposition to Disease. Liver Diseases / genetics

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485898.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


14. Longhi MS, Mitry RR, Samyn M, Scalori A, Hussain MJ, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D: Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology; 2009 Jul;50(1):130-42
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.
  • Studies in AIH have focused on autoreactive CD4 and CD8 T cells and impairment of CD4+CD25+ regulatory T cells (T-regs), whereas little is known about the role of monocytes and their relationship with T-regs.
  • We have investigated 51 patients with autoimmune liver disease (AILD) and 27 healthy subjects, finding that monocytes were higher in number (P = 0.044), had a more vigorous spontaneous migration (P < 0.0005 in patients with inactive disease [ID], and P < 0.001 in those with active disease [AD]), displayed a higher tumor necrosis factor alpha (TNF-alpha) over interleukin (IL)-10 production (P = 0.07 in ID and P = 0.0005 in AD), and expressed higher levels of Toll-like receptor (TLR) 4 (P = 0.048 in ID and P = 0.03 in AD).
  • Addition of conventional T-regs (cT-regs) in AILD enhanced monocyte migration (P = 0.05 in ID and P = 0.08 in AD), magnified TNF-alpha over IL-10 production (P = 0.0005 in ID and P = 0.006 in AD), and markedly increased TLR4 expression levels (P = 0.01 in ID and P = 0.004 in AD), whereas in normal subjects it either restrained or left unchanged monocyte function.
  • Addition of tT-regs to monocytes decreased monocyte migration (P = 0.03) and promoted IL-10 production (P = 0.009), leaving unchanged TLR4 expression in healthy subjects, whereas in patients with AILD it induced only a marginal increase in IL-10 production (P = 0.045 in ID and P = 0.13 in AD).
  • CONCLUSION: Monocyte overactivation and inability of cT-regs and tT-regs to restrain it may contribute to the loss of immune tolerance and perpetuation of the autoimmune attack in AILD.
  • [MeSH-major] Autoimmune Diseases / immunology. Leukocytes, Mononuclear / physiology. Liver Diseases / immunology. T-Lymphocytes, Regulatory / physiology

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437492.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Pujol RM, Gallardo F, Servitje O, Martí RM, Bordes R, García-Muret MP, Estrach MT, Nomdedeu JF: Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases. J Dermatol; 2005 Jul;32(7):541-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases.
  • Epithelioid granuloma formation has rarely been observed in specific cutaneous lesions from T-cell lymphomas other than those of mycosis fungoides/Sézary syndrome (MF/SS).
  • Three patients diagnosed with nodal and/or extranodal (tonsillar) non-Hodgkin's peripheral T-cell lymphoma (PTCL) and one patient with angioimmunoblastic T-cell lymphoma (AILD), developed specific cutaneous involvement showing prominent epithelioid cell and/or granulomatous inflammation.
  • Sarcoid-like granulomas were observed in two patients (one of them presented a granuloma annulare-like pattern in early lesions), granulomatous panniculitis was noted in one patient and in one patient with AILD, masses of epithelioid cells were noted.
  • The clinicopathological features of cutaneous involvement by PTCL showing a florid epithelioid and/or granulomatous cell reaction are reviewed.
  • [MeSH-major] Epithelioid Cells / pathology. Granuloma / complications. Lymphoma, T-Cell, Peripheral / complications. Skin Diseases / complications


16. Welch KD, Wen B, Goodlett DR, Yi EC, Lee H, Reilly TP, Nelson SD, Pohl LR: Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol; 2005 Jun;18(6):924-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of potential susceptibility factors in drug-induced liver disease.
  • Drug-induced liver disease (DILD) causes significant morbidity and mortality and impairs new drug development.
  • As an approach to better understand the multifactorial basis of DILD, we compared the hepatic proteome of mice that are resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD), using solution-based isotope-coded affinity tag (ICAT) liquid chromatography mass spectrometry.
  • Several novel factors were identified that were more highly expressed in the livers of SJL mice, including those involved in stress response, cell proliferation and tissue regeneration, and protein modification, implicating these proteins as potential hepatoprotective factors.
  • There was also a selective loss of several mitochondrial proteins from the livers of the susceptible C57Bl/6 mice, suggesting that the loss of functional mitochondria may indeed play a role in AILD.
  • [MeSH-minor] Acetaminophen / toxicity. Affinity Labels / chemistry. Animals. Chromatography, Affinity. Disease Susceptibility / metabolism. Drug Resistance. Liver Diseases / metabolism. Liver Diseases / mortality. Male. Mass Spectrometry. Mice. Mice, Inbred C57BL. Mitochondria, Liver / drug effects. Mitochondria, Liver / metabolism. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962927.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES 07033; United States / NCRR NIH HHS / RR / P51 RR 00166
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


17. Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N: Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract; 2010 Apr 15;206(4):270-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases.
  • We report two patients, a 68-year-old man (Case 1) and a 66-year-old man (Case 2), with polyclonal gammopathy, lymphadenopathy, thrombocytopenia, and high platelet-associated IgG (PAIgG) level.
  • We initially diagnosed them as having angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
  • From confirmation of clear cells by careful observation and detection of rearrangement bands of T cell receptors by Southern blot hybridization analysis, we finally concluded that their diagnoses were compatible with angioimmunoblastic T-cell lymphoma (AILT).
  • AILT with autoimmune thrombocytopenia (AIT) is very rare, and all the reported cases were Japanese ones.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Purpura, Thrombocytopenic, Idiopathic / pathology
  • [MeSH-minor] Aged. Blotting, Southern. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19442454.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, has been explored in recent years with little experiences.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • The patients were stratified according to their International Prognostic Index (IPI), disease status at the time of transplant and histology type.
  • RESULTS: Twenty-nine subjects were identified, with a median age of 51; 13 patients had Anaplastic T cell, 18 patient had PTCL-nos, and 6 patients with angioimmunoblastic T cell lymphoma.
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.
  • A multivariate analysis and new risk stratification based on the IPI score system and disease status at time of transplant were employed.
  • CONCLUSIONS: The status at time of transplant with new methods for evaluation of minimal residual disease may help in assessing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Oki M, Isozaki M, Nakamura N, Kikuchi A, Tsuchiya T, Arbogast P, Ogawa Y, Ando K: A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL).
  • : e19521 Background: Nodal peripheral T-cell lymphoma (PTCL) is uncommon lymphoma with various subtypes and poor prognosis.
  • However, the superiority of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has remained inconclusive.
  • We conducted a retrospective study of fifty six patients with three major nodal PTCL, histologically classified as PTCL-not specified (NOS, n=29), angioimmunoblastic T-cell lymphoma (AITL, n=19), and ALK-negative anaplastic large cell lymphoma (ALCL, n=8) who underwent ASCT (n=14) or not (n=42) after CT in Tokai University Hospital, Ebina General Hospital, and Hadano Red Cross Hospital, Kanagawa, Japan between 1997 and 2008.
  • METHODS: Retrospective, multicenter cohort study by time-dependent or non-time-dependent multivariate survival analysis with Cox proportional hazard regression.
  • In non-time-dependent analysis, both ASCT and sIL-R were significant prognostic factors for overall survival (OS).
  • On the other hand, ASCT was only important effect on progression-free survival (PFS) by non-time-dependent analysis, which HR was 0.20 (95%CI: 0.07-0.55, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Amarapurkar DN, Patel ND: Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol; 2007 Dec;22(12):2112-7
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of autoimmune liver diseases in western India.
  • BACKGROUND AND AIM: The prevalence and spectrum of autoimmune liver diseases (AILDs) in India are rarely reported in comparison to the West.
  • METHOD: During a study period of 7 years, all patients with chronic liver diseases (CLDs) were evaluated for the presence of AILDs on the basis of clinical, biochemical, imaging, serological, and histological characteristics.
  • RESULTS: Of a total of 1760 CLD patients (38.1% females), 102 patients (5.7%) had an AILD.
  • A total of 75 (11.2%) female patients had an AILD.
  • Among males, 27 (2.4%) had an AILD.
  • The prevalence of AILDs in women increased from 11.2% to 45.7% and in men from 2.4% to 10.3%, after excluding alcohol, hepatitis B virus, and hepatitis C virus as a cause of CLD.
  • Of the AILDs, autoimmune hepatitis (AIH) was present in 79 patients (77.4%), followed in descending order by primary biliary cirrhosis (PBC) in 10 patients (9.8%), PBC/AIH true overlap syndrome in six patients (5.8%), primary sclerosing cholangitis (PSC) in five patients (4.9%), and PBC/AIH switchover syndrome in two patients (1.9%).
  • Associated known autoimmune diseases were found in 40 (39.2%) patients.
  • CONCLUSIONS: AILDs are not uncommon in India.
  • They should be suspected in all cases of CLDs, especially in middle-aged women who do not have problems with alcoholism and who are without viral etiology, as well as in all patients with known autoimmune diseases.
  • [MeSH-major] Autoimmune Diseases / epidemiology. Liver Diseases / epidemiology

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623034.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


21. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol; 2006 Jun 1;24(16):2472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.
  • PURPOSE: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival.
  • We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD).
  • RESULTS: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD.
  • The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD2; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, CD4; 0 / Antigens, CD5; 0 / Antigens, CD7; 0 / Antigens, CD8; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


22. Bourdi M, Eiras DP, Holt MP, Webster MR, Reilly TP, Welch KD, Pohl LR: Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol; 2007 Feb;20(2):208-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male C57Bl/6 wild type (WT) and mice deficient in one or more cytokines were treated with 120 mg/kg APAP.
  • IL-6 appeared to have a causal role in controlling the unique susceptibility of IL-10/4-/- mice to APAP-induced liver disease (AILD) because IL-6 neutralizing antibody reversed the high sensitivity of these mice to AILD.
  • Moreover, IL-10/4/6-/- mice were also resistant to the enhanced susceptibility to AILD and expressed relatively low levels of most proinflammatory factor genes that were elevated in the IL-10/4-/- mice.
  • In conclusion, liver homeostasis following AILD appears to be highly dependent on the activities of both IL-10 and IL-4, which together help prevent overexpression of IL-6 and other potential hepatotoxic factors.
  • [MeSH-major] Acetaminophen / toxicity. Disease Models, Animal. Drug-Induced Liver Injury / metabolism. Interleukin-10 / deficiency. Interleukin-4 / deficiency. Interleukin-6 / physiology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Arginase / antagonists & inhibitors. Arginase / biosynthesis. Biomarkers / blood. Genetic Predisposition to Disease. Glutathione / drug effects. Glutathione / metabolism. Interferons / biosynthesis. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Mice, Knockout. Nitric Oxide / biosynthesis. Nitric Oxide / blood

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305405.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 31C4KY9ESH / Nitric Oxide; 362O9ITL9D / Acetaminophen; 9008-11-1 / Interferons; EC 3.5.3.1 / Arginase; GAN16C9B8O / Glutathione
  •  go-up   go-down


23. Zeniya M, Watanabe F, Morizane T, Shibata M, Maeyama S, Kage M, Nakanuma Y, Toda G, Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour, and Welfare of Japan: Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J Gastroenterol; 2005 Dec;40(12):1148-54
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.
  • BACKGROUND: Diagnosing autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis, and other autoimmune liver diseases remains an imperfect process.
  • METHODS: We conducted a national survey and identified 988 cases of liver disease which did not satisfy the inclusion criteria for any liver disease of known etiology.
  • We expected these cases to include autoimmune liver disease (AILD) and its variant forms.
  • We selected 269 prototype cases for which histological re-evaluation of liver biopsy by independent expert hepatopathologists and the original diagnosis coincided.
  • We did a multiple logistic regression analysis to determine explanatory variables that would distinguish cases of AIH and PBC from those of non-AIH and non-PBC, respectively.
  • We constructed a multivariable diagnostic formula that gave AIH and PBC disease probabilities and validated it in a study of an additional 371 cases (validation group).
  • RESULTS: Based on the results of the statistical analysis, we selected three laboratory tests and four histological features as independent variables correlated to the diagnosis of both AIH and PBC.
  • For the validation group, assuming that the original diagnosis was correct, the sensitivity and specificity for AIH were 86.3% and 92.4%, respectively.
  • A detailed analysis of inconsistent cases showed that the diagnosis based on the formula had given the correct diagnosis, for either AIH or PBC, except for 5 cases (1.3%) in which disease probability was low for both.
  • CONCLUSIONS: A seven-variable formula based on three laboratory tests and four histological features gives significant information for the diagnosis of AILD.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Liver Diseases / diagnosis
  • [MeSH-minor] Algorithms. Cholangitis, Sclerosing / diagnosis. Female. Hepatitis, Autoimmune / diagnosis. Humans. Liver Cirrhosis, Biliary / diagnosis. Male. Middle Aged. Models, Theoretical. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Dec;40(12):1163-6 [16378184.001]
  • (PMID = 16378179.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


24. Hagberg H, Pettersson M, Bjerner T, Enblad G: Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol; 2005;22(2):191-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
  • A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated with a human monoclonal anti-CD4 antibody (HuMax-CD4) iv once weekly for 10 wk.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD4 / immunology. Immunoblastic Lymphadenopathy / therapy. Immunotherapy. Lymph Nodes / drug effects. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965283.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD4
  •  go-up   go-down


25. Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N: The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma; 2005 Jul;46(7):999-1006
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
  • Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets.
  • We examined the effect of thalidomide on T-lymphocyte subsets in 18 patients with MDS, 6 patients with MM, 4 patients with IM, and 3 patients with angioimmunoblastic lymphoma (AILD).
  • These patients had either a relapse or progressive disease following cytotoxic chemotherapy including high-dose chemotherapy with autologous stem cell support.
  • T-lymphocyte subsets (CD4+, CD8+) were measured by fluorescence-activated cell sorter (FACS) before and during treatment with thalidomide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. CD4-CD8 Ratio. Hematologic Diseases / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019550.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


26. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol; 2008 Sep;26(3):152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
  • We studied the clinico-pathologic features and treatment outcome of patients with peripheral T-cell lymphoma (PTCL).
  • This study included 215 patients with T/natural killer (NK)-cell lymphoma, including 59 with PTCL-unspecified (PTCL-U), 42 with angioimmunoblastic T-cell lymphoma (AILT) and 20 with anaplastic large-cell lymphoma (ALCL).
  • Most of the analyses were performed on patients with AILD, ALCL and PTCL-U.
  • The patients with AILT and PTCL-U tended to be older than those with ALCL.
  • Stage III/IV disease was seen in 90.5% of the AILT cases, 55% of the ALCL cases and 67.8% of the PTCL-U cases.
  • In addition, 61.9% of the AILT cases had an international prognostic index (IPI) of H-I or H risk.
  • The 5-year progression-free survival (PFS) and overall survival (OS) rates were 72.2 and 76.1% among the ALCL cases, 40.7 and 42.2% among the PTCL-U cases and 31.2 and 49.3% among the AILT cases, respectively.
  • The 5-year PFS and OS rates among patients who received CHOP therapy, CyclOBEAP [cyclophosphamide (CPA), vincristine (VCR), bleomycine, etoposide, doxorubicin (DXR), prednisone (PDN)] therapy or autologous stem cell transplantation were: 22 and 25.7%, 59 and 61.7% or 33.3 and 60%, respectively.
  • PTCL-U is a heterogeneous disease with regard to histological type and pathological state.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18395866.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Troxell ML, Schwartz EJ, van de Rijn M, Ross DT, Warnke RA, Higgins JP, Natkunam Y: Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):297-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma is characterized by a paracortical proliferation of medium to large neoplastic T cells, often with clear cytoplasm, in a background of arborizing high endothelial venules, many surrounded by follicular dendritic cells (FDCs).
  • The authors stained a collection of 45 angioimmunoblastic T-cell lymphomas with CD21, CD23, CNA.42, cystatin A, and fascin for direct comparison of FDC staining characteristics in this setting.
  • CD21 highlighted the expected dendritic network of cell processes, within residual follicles and outside of follicles, often adjacent to proliferating vessels.
  • Cystatin A stained the cytoplasm of follicular dendritic cells within and outside of follicles; however, staining was often not sharply localized to dendritic cell processes, and scoring was further complicated by reactivity with other cell types in over half of the cases.
  • Likewise, fascin stained a variety of cell types, including strong staining of interdigitating dendritic-like cells, moderate staining of endothelial cells, and only weak staining of follicular dendritic cells within and outside of follicles.
  • Thus, CD21 remains the most reliable marker of follicular dendritic cells in angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280657.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 146808-54-0 / fascin
  •  go-up   go-down


28. Willenbrock K, Bräuninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol; 2007 Sep;138(6):733-9
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases.
  • Secondary lymphomas occurring in the setting of angioimmunoblastic T-cell lymphoma (AILT) are considered to be rare.
  • A previous study detected a dysregulated hypermutation process in B-cells of AILT.
  • The present study aimed at estimating the frequency of B-cell lymphomas in AILT.
  • By studying the expression of EBV and activation-induced cytidine deaminase (AID) as an indicator of hypermutating cells, we assessed whether B-cell lymphoproliferations in AILT were strictly associated with EBV and whether hypermutation might contribute to lymphomagenesis.
  • Among 161 cases of AILT, diagnosed between 1996 and 2005 at the lymph node registry, Frankfurt, Germany, 19 cases were detected that also had B-cell non-Hodgkin lymphoma (NHL) and two cases had classical Hodgkin lymphoma (HL).
  • AID was expressed in AILT in large cells disseminated in the tissue, implying that the process of somatic hypermutation is ongoing in AILT, although the GC architecture is disrupted.
  • This might be relevant in the development of secondary lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / virology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Cell Proliferation. Clone Cells. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Rearrangement, B-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. RNA, Viral / analysis. Somatic Hypermutation, Immunoglobulin. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672882.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Viral; EC 3.4.24.11 / Neprilysin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


29. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


30. Wang FX, Zhang XJ, Pan L, Qiao SK, Guo XL, Dong ZR: [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):862-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia].
  • Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell lymphoma often complicated autoimmune phenomena such as autoimmune cytopenia, and is a truly rare type of NHL.
  • In order to investigate the clinical features, pathological manifestation of this lymphoma, and to explore its therapy protocol, a 37-years old patient with AILT was investigated.
  • The warm type autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) were co-existed.
  • In conclusion, the AITL patient complicated with AIHA and PRCA was successfully diagnosed, the lymphonode biopsy and bone marrow smear showed more significant, the chemotherapy protocol of CHOP-E can give some effect to cure such angioimmunoblastic T cell lymphoma.


31. Hawley RC, Cankovic M, Zarbo RJ: Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med; 2006 Nov;130(11):1707-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.
  • Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency.
  • Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states.
  • However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported.
  • We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma.
  • The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion.
  • Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076535.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


32. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N: c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2007 Nov;31(11):1695-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Maf expression in angioimmunoblastic T-cell lymphoma.
  • We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT).
  • In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically.
  • Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type.
  • Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26).
  • Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples.
  • Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test).
  • These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / chemistry. Proto-Oncogene Proteins c-maf / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059226.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / MAF protein, human; 0 / Proto-Oncogene Proteins c-maf; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


33. Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol; 2007 Jun;137(5):416-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
  • Bone marrow (BM) biopsy is often performed early in the evaluation of patients with angioimmunoblastic T-cell lymphoma (AITL), and may be the first diagnostic tissue sample; yet the BM histopathology associated with this disease has not been well described.
  • Seven (54%) were involved by AITL, which was characterised by paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes, histiocytes and eosinophils.
  • As in lymph nodes, the lymphomatous infiltrate in some BMs contained numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma, respectively.
  • When BM biopsy preceded the diagnosis of AITL, these secondary changes were misinterpreted as chronic myeloproliferative disease (n = 2), or plasma cell dyscrasia (n = 2).
  • The spectrum of BM findings in AITL patients is important to recognise for early and accurate diagnosis in this disease.
  • [MeSH-major] Bone Marrow Examination. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Chemokine CXCL13. Chemokines, CXC / analysis. Diagnosis, Differential. Eosinophils / pathology. Histiocytes / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Neprilysin / analysis. Red-Cell Aplasia, Pure / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488486.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


34. de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol; 2010 Mar;148(5):673-89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) entity with peculiar clinical and pathological features.
  • The recent identification of follicular helper T (T(FH)) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS).
  • Deciphering the pathogenesis of the disease is needed to identify targets for new therapies that are expected to improve the poor outcome of AITL patients, when treated with conventional chemotherapy regimens.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / physiopathology
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cytogenetics. Diagnosis, Differential. Humans. Immunophenotyping. Prognosis. T-Lymphocytes, Helper-Inducer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961485.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 170
  •  go-up   go-down


35. Bruneau J, Canioni D, Renand A, Marafioti T, Paterson JC, Martin-Garcia N, Gaulard P, Delfau MH, Hermine O, Macintyre E, Brousse N, Asnafi V: Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):570-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is the most frequent nodal T-cell lymphoma and is characterized by a polymorphic lymph node infiltrate, various dysimmune disorders, and a poor prognosis.
  • Regulatory T-cells (Treg) play an emerging role in the prognosis of non-Hodgkin B-cell lymphoma and mediate significant autoreactive T-cell suppression.
  • In this report, we demonstrate that numbers of Treg are significantly decreased in AITL lymph nodes [n = 30, 91 (40-195) per high power fields] compared with follicular lymphoma [n = 19, 179 (86-355)] and reactive lymph nodes [n = 8, 186 (140-265)].
  • Moreover, the few Treg in lymph nodes of AITL are resting Treg (rTreg) and have a naive CD45RA+, PD1-, and ICOS- phenotype [n = 5, 57% of Treg are CD45RA+ (16-96)], in contrast to the Treg in follicular lymphomas [n = 5, 7.4% (1-13)] or reactive lymph nodes [n = 7, 18.6% (6-48)].
  • Interestingly, Treg depletion was not observed in AITL peripheral blood at diagnosis.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphocyte Depletion. Lymphoma, T-Cell / immunology. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1892-903 [16791882.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2808-16 [16493037.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):802-10 [16819321.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1693-700 [16818676.001]
  • [Cites] Immunity. 2008 Jun;28(6):870-80 [18513999.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):682-90 [19295409.001]
  • [Cites] Immunity. 2009 Jun 19;30(6):899-911 [19464196.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):637-42 [3805286.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4051-61 [17371959.001]
  • (PMID = 20566750.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2913366
  •  go-up   go-down


36. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • In a 36-year-old female patient, evaluated for moderate leukocytosis, peripheral and abdominal lymphadenopathy AITL was diagnosed in March 2008, based on results of fine-needle aspiration cytology (FNAC) of the enlarged cervical and supraclavicular lymph nodes.
  • The diagnosis was also confirmed by immunophenotyping and histopathology of the cervical lymph nodes.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • In April 2009 the patient was hospitalized because of fever, pancytopenia, hyperbilirubinemia and peripheral lymphadenopathy.
  • CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in good partial response of the disease.
  • Reduced intensity allogeneic stem cell transplantation performed thereafter, resulted in complete remission of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


38. Sekine R, Ohno N, Uchimura K, Oyaizu N, Tojo A: [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2007 Nov;48(11):1498-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma].
  • A 73-year-old woman was admitted with generalized lymphadenopathy, marked protrusion of the abdomen, severe systemic edema, oliguria, and dyspnea.
  • Histological examination of a cervical lymph node specimen showed a typical structure of angioimmunoblastic T-cell lymphoma.
  • CT scan revealed whole paraaortic lymphadenopathy, marked edematous lesions in the subcutaneous tissues and mesenterium, but small amounts of pleural effusion and ascites.
  • [MeSH-major] Edema / etiology. Immunoblastic Lymphadenopathy / blood. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell, Peripheral / blood. Lymphoma, T-Cell, Peripheral / complications. Vascular Endothelial Growth Factors / blood

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080509.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


39. Lachenal F: [Angioimmunoblastic T-cell lymphoma]. Presse Med; 2007 Nov;36(11 Pt 2):1655-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma].
  • [Transliterated title] Lymphomes T angio-immunoblastiques.
  • Angioimmunoblastic T-cell lymphoma most often affects the elderly.
  • Patients present with generalized lymphadenopathy and systemic symptoms; half also have hepatomegaly, splenomegaly and a rash.
  • Lymph node biopsy is needed to confirm this diagnosis.
  • Genetic analysis that reveals a monoclonal T-cell population is also relevant.
  • Autologous stem cell transplantation is proposed to the youngest.
  • [MeSH-major] Immunoblastic Lymphadenopathy. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587541.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


40. Carbone A, Gloghini A, Cabras A, Elia G: The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol; 2009 May;145(4):468-80
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Germinal centre-derived lymphomas seen through their cellular microenvironment.
  • The human lymph node is a complex tissue resulting from the microenvironmental organisation of different cell populations linked by topographical and/or functional relationships.
  • On the whole, GC exerts a role in B cell physiology and malignancy.
  • In GC-derived lymphomas, gene expression profiling studies have raised the possibility that survival of the affected patients may be associated with signatures preferentially expressed in non-malignant T cells and macrophages and/or dendritic cells.
  • Immunohistological analyses in lymphoma biopsy samples have confirmed that the biological behaviour and tumour progression may be influenced by the tumour microenvironment.
  • This review will examine GC-derived lymphomas, including follicular lymphomas, Hodgkin lymphomas and angioimmunoblastic T-cell lymphoma, through their integrated cellular microenvironment, highlighting those findings which may serve as a useful surrogate marker for tumour diagnosis or tumour progression, together with key molecules involved in tumour development.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Expression Regulation, Neoplastic. Germinal Center / physiology. Hodgkin Disease / immunology. Lymphoma, Follicular / immunology. Lymphoma, T-Cell / immunology
  • [MeSH-minor] Disease Progression. Humans. Immunohistochemistry. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344401.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


41. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • The disease can be classified into three categories based on histological findings: 3 cases of AILT with hyperplastic germinal centers, 4 cases of typical AILT, and 4 cases of AILT with numerous clear cells.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival.
  • The survival time of AILT demonstrated a wide range.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol; 2009 Jun;22(6):753-61
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers.
  • Angioimmunoblastic T-cell lymphoma is an aggressive peripheral T-cell lymphoma whose natural history is not fully understood.
  • The accurate recognition of Angioimmunoblastic T-cell lymphoma with pattern I remains a challenge and therefore the aim of this study is to phenotypically and morphologically characterize this variant with the use of the follicular helper T-cell (T(FH)) markers PD1, CXCL-13 and ICOS.
  • Out of the 88 Angioimmunoblastic T-cell lymphoma cases reviewed, 10 showed hyperplastic follicles.
  • Molecular probe methods for the detection of T-cell and B-cell clonality, as well as in-situ hybridization probes for EBV RNA expression, were carried out to leave no question as to the establishment of the diagnosis in each case.
  • By contrast, CD10 was found to only weakly label the neoplastic T cells, with only 5-10% of the target cell population staining for this marker.
  • Clinically, 8/9 cases presented with stage IIIB/IVB and in 2/10 cases consecutive biopsies showed 'progression' from pattern I to classical Angioimmunoblastic T-cell lymphoma.
  • In conclusion we have shown that the T(FH) cells markers PD1, CXCL13 and ICOS are useful adjuncts in the diagnosis of Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres.
  • PD1 also highlighted the presence of neoplastic cells in the outer zone of lymphoid follicles, suggesting that Angioimmunoblastic T-cell lymphoma (pattern I) may originate from T(FH) cells in this region, in accordance with previous immunological studies.
  • As the majority of cases in our series presented clinically with advanced stage disease, progression from pattern I to classical Angioimmunoblastic T-cell lymphoma may represent histological evolution rather than clinical progression.
  • [MeSH-major] Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / immunology. Chemokine CXCL13 / metabolism. Female. Humans. Immunohistochemistry. Inducible T-Cell Co-Stimulator Protein. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Programmed Cell Death 1 Receptor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329936.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Chemokine CXCL13; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


43. Ortonne N, Dupuis J, Plonquet A, Martin N, Copie-Bergman C, Bagot M, Delfau-Larue MH, Gaulier A, Haioun C, Wechsler J, Gaulard P: Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol; 2007 Jul;31(7):1068-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL).
  • Skin manifestations of angioimmunoblastic T-cell lymphoma (AITL) are frequent, sometimes as first manifestations of the disease.
  • In the absence of a specific marker for neoplastic cells, diagnosis of AITL in skin biopsies is often difficult.
  • A few CD10 lymphocytes were found in only 2 samples of the AITL group, the identification of which was hampered by the presence of a dermal CD10 cell population with dendritic features.
  • In another case, a diagnosis of cutaneous marginal zone B-cell lymphoma had been proposed.
  • In conclusion, this study shows that neoplastic AITL CXCL13 T cells localize in the skin and that accurate diagnosis of AITL lesions can be done in skin specimens using CXCL13 immunostaining on paraffin-embedded tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokines, CXC / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592274.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


44. Papadavid E, Panayiotides I, Dalamaga M, Katoulis A, Economopoulos T, Stavrianeas N: Cutaneous involvement in angioimmunoblastic T-cell lymphoma. Indian J Dermatol; 2010 Jul-Sep;55(3):279-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive non-Hodgkin's nodal peripheral T-cell lymphoma characterized by general lymphadenopathy, night sweats, fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia, and cutaneous involvement.
  • We present a rare case of AITL cutaneous involvement mimicking toxic erythema recurring with AITL relapse and suggesting a precursor of disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063526.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2965920
  • [Keywords] NOTNLM ; Angioimmunoblastic T-cell lymphoma / cutaneous involvement
  •  go-up   go-down


45. Zhang D, Saunders CJ, Zhao W, Davis M, Cunningham MT: The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia. Am J Hematol; 2009 Sep;84(9):606-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia.
  • T cells coexpressing CD3 and CD10 are a characteristic feature of angioimmunoblastic T-cell lymphoma (AITL) [1].
  • However, they are not unique to AITL, as these cells are also present in B cell lymphoma and reactive lymphoid hyperplasia [2].
  • To determine the significance of CD3+ CD10+ T cells, we used flow cytometry with cell sorting and molecular biology techniques for T cell gene rearrangement to study T cells from patients with AITL, B cell lymphoma, and reactive lymph node hyperplasia.
  • We found that CD3+ CD10+ T cells in B cell lymphoma and reactive lymphoid hyperplasia were polyclonal.
  • These findings illustrate the differences between early and late lymphoma and could be important for the diagnosis of AITL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Pseudolymphoma / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Clone Cells. Humans. Immunoblastic Lymphadenopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650143.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


46. Alizadeh AA, Advani RH: Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol; 2008 Dec;6(12):899-909
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and complex lymphoproliferative disorder, clinically characterized by widespread lymphadenopathy, extranodal disease, immune-mediated hemolysis, and polyclonal hypergammaglobulinemia.
  • Significant progress has been made in the understanding of AITL since its recognition as a clonal T-cell disorder with associated deregulation of B-cells and endothelial cells within a unique malignant microenvironment.
  • We discuss recent developments in the understanding of the pathogenesis of AITL at a cellular and molecular level, including the implication of the follicular helper T-cell as the corresponding cell of origin, the roles of Epstein-Barr virus, B-cell deregulation, angiogenesis, and other signaling pathways in AITL, and the therapeutic implications of these findings.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209140.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 2S9ZZM9Q9V / Bevacizumab; 4F4X42SYQ6 / Rituximab; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 100
  •  go-up   go-down


47. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P, Groupe d'Etude des Lymphomes de l'Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood; 2008 May 1;111(9):4463-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
  • To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials.
  • In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival.
  • In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Chemokine CXCL13 / analysis. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunoblastic Lymphadenopathy. Middle Aged. Neprilysin / analysis. Prednisone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):309-14 [10917533.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] Hematol J. 2001;2(6):393-5 [11920279.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Cancer. 1978 Feb;41(2):578-606 [630540.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):318-21 [6861074.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):208-12 [3802012.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1625-9 [2924270.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Leukemia. 1991 Oct;5(10):892-5 [1961023.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1993 Jul 1;82(1):241-6 [8391875.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2354-5 [8822958.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):193-8 [9143398.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):601-3 [9261530.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Int J Hematol. 1998 Apr;67(3):319-29 [9650454.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):853-65 [16261173.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1110-1 [16861359.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 18292286.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2343588
  • [Investigator] Abdalsamad I; Dagger MF; Allard C; Angonin R; d'Anjou J; Audhuy B; Audouin J; Auzanneau G; Baglin AC; Bacilli C; Bastion Y; Baumelou E; Bensimon P; Berger F; Biron P; Blaise AM; Blanc M; Boman-Ferrand F; Boehn A; Boniver J; Bordes M; Bordessoule D; Bosly A; Bosq J; Bouabdallah R; Boucheron S; Bouvier J; Brice P; Brière J; Brousse N; Brousset P; Bryon PA; Caillot D; Carbillet JP; Casasnovas RO; Caulet T; Cazals D; Charlotte F; Charvillat L; Chesneau AM; Christian B; Coiffier B; Conroy T; Cordier JF; Cordonnier C; Clauvel JP; Deconinck E; Delage M; Delannoy A; Delmer A; Delos M; Delsol G; Devidas A; Diebold J; Diviné M; Dombret H; Doyen C; Duplay H; Dupriez B; Duval C; Eisenmann JC; Elbaz D; Emberger JM; Epardeau B; Fabiani B; Felman P; Fermand JP; Fermé C; Ferrand A; Ffrench M; Fievez M; Fillet G; Fonck Y; Froment N; Gabarre J; Galian P; Gasser O; Gaulard P; Gisselbrecht C; Gosselin B; Goutier C; Guy H; Guyotat D; Haioun C; Hamels J; Herbrecht R; Hopfner O; Horschowski N; Huguet F; Jacomy P; Jaubert J; Jeandel R; Kerneis Y; Knopf JP; Kuentz M; Labouyrie E; Lancien B; Laurent G; Lavergne A; Lavignac C; Leblond V; Lecomte-Houke M; Léderlin P; Lejeune F; Leger-Ravet MB; Loire R; Marcellin R; Marolleau JP; Marit G; Martin C; Marty-Double C; De Mascarel A; Méhaut S; Merlio JP; Merignargues C; Micléa JM; Michaux JL; Molina T; Monconduit M; Morel P; Morvan F; Mosnier JF; Nédellec G; Netter-Pinon C; Noel H; Nouvel C; Patey M; Peaud PY; Perie G; Peuchmaur M; Petrella T; Pignon B; Platini C; Pluot M; Pollet JP; Pujade-Lauraine E; Raphael M; Raymond-Gelle MC; Reiffers J; Reyes F; Rochet M; Rossi JF; Roucayrol AM; Rozenbaum A; Salles G; Schill H; Sebban C; Simon M; Solal-Céligny P; Straub P; Suc E; Sutton L; Symann M; Tertian G; Thiebaut S; Thyss A; Tilly H; Travade P; Trillet V; Vernant JP; Wendum D; Xerri L
  •  go-up   go-down


48. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
  • She had previously had a positive protein derivative test with a negative chest X-ray; her medical history was also remarkable for a mitral valve prolapse.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


49. Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J: Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol; 2009 May;131(5):640-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement.
  • We retrospectively reviewed the clinical and laboratory data and bone marrow (BM) histomorphologic features in 33 angioimmunoblastic T-cell lymphoma (AITL) cases.
  • Paraffin-embedded BM core biopsy specimens were reacted immunohistochemically with antibodies to pan-T-cell markers, CD20, CD10, CD21, and bcl-6.
  • Morphologic features included nodular or interstitial infiltration in a paratrabecular distribution, periodic acid-Schiff-positive intercellular materials, mixed infiltrates of T and B cells, presence of clear cells, and blood vessel proliferation.
  • Seven cases with BM involvement were interpreted as negative for lymphoma initially, mainly owing to insufficient information in nodal biopsy specimens.
  • Several clinical and laboratory features indicate BM involvement of AITL at diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369622.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Inoue D, Kimura T, Shimoji S, Mori M, Nagai Y, Tabata S, Kurata M, Matsushita A, Nagai K, Maruoka H, Yamashita E, Takahashi T: [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis]. Rinsho Ketsueki; 2009 Feb;50(2):87-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis].
  • A 73-year-old man was hospitalized with fever, erythema, generalized superficial lymphadenopathy and marked neutropenia in July 2007.
  • Hematologic examination demonstrated a white blood cell count of 1,400/microl with 0% neutrophils, and 18% abnormal lymphocytes.
  • A diagnosis of drug-induced agranulocytosis was made.
  • Although neutrophil counts immediately returned to normal levels in response to filgrastim, fever, skin rash and systemic lymphadenopathy were all persistent.
  • Based on the histologic findings, PCR, and immunohistologic analyses, he was diagnosed with angioimmunoblastic T cell lymphoma (AILT) in leukemic state.
  • The response of the lymphoma to conventional chemotherapy (CHOP and ESHAP) was poor.
  • The treatment resulted in a partial remission of AILT including disappearance of circulating lymphoma cells.
  • To our knowledge, this is the first published report of AILT complicated by drug-induced agranulocytosis.
  • [MeSH-major] Acetaminophen / adverse effects. Agranulocytosis / chemically induced. Analgesics, Non-Narcotic / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, T-Cell / etiology

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265300.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Immunosuppressive Agents; 362O9ITL9D / Acetaminophen; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


51. Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, Joh K, Imai H: Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma. Am J Kidney Dis; 2006 Jul;48(1):e3-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma.
  • A 70-year-old man with angioimmunoblastic T-cell lymphoma developed acute renal failure.
  • These findings suggest that cryoglobulin, which consists of monoclonal IgM-lambda, induced glomerular thrombi and acute renal failure in a patient with angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Thrombosis / etiology. Thrombosis / immunology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797380.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


52. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D: Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol; 2008 Jul;39(7):1050-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
  • PD-1 expression was recently reported in some T-cell non-Hodgkin lymphoma (NHL) subtypes, but the expression profile of PD-1 and its ligands (PD-L1 and PD-L2) in B-NHLs remains largely to be characterized.
  • A series of 161 lymphoma tissue and 11 blood samples was analyzed using either immunohistochemistry or flow cytometry.
  • In B-NHLs, PD-1 was mainly expressed in reactive T cells; but expression was also noted in neoplastic B cells from small lymphocytic lymphoma (SLL, 12/13), grade III follicular lymphoma (3/3), and diffuse large cell lymphoma (2/25).
  • In contrast, neoplastic B cells from mantle cell lymphoma (0/11), marginal zone lymphoma (0/12), Burkitt lymphoma (0/3), and grade 1 to 2 follicular lymphoma (0/40) were PD-1 negative.
  • PD-L1 and PD-L2 were negative in small B-cell lymphomas, including B-SLL.
  • PD-1 expression in T-NHLs was restricted to the angioimmunoblastic subtype (8/8).
  • Because the anti-PD-1.6.4 antibody works on paraffin sections, it represents a useful tool to differentiate SLL/CLL from other small B-cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / metabolism. Immunoblastic Lymphadenopathy / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Animals. Diagnosis, Differential. Flow Cytometry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Mice. Mice, Inbred BALB C. Programmed Cell Death 1 Receptor

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Nov;41(11):1655. Seriari, Nacer [corrected to Serriari, Nacer]
  • (PMID = 18479731.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


53. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS: Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2007 Apr;48(4):716-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
  • The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period.
  • At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement.
  • [MeSH-major] Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Apr;48(4):645-6 [17454617.001]
  • (PMID = 17454629.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


54. Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H, Uekusa T: Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract; 2010 Jan 15;206(1):9-13
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma.
  • Patients affected by autoimmune diseases (rheumatoid arthritis (RA), psoriasis, and dermatomyositis) treated with methotrexate (MTX) develop lymphoproliferative disorders (LPDs).
  • These cases have been reported to be diffuse large B-cell lymphoma, Hodgkin lymphoma, or polymorphous post-transplant LPDs.
  • However, angioimmunoblastic T-cell lymphoma (AITL) is extremely rare in the medical literature.
  • The affected lymph nodes showed the histological finding of AITL: polymorphous infiltrates, mainly T-cells and arborizing high endothelial venules.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis. Lymphoproliferative Disorders / chemically induced. Lymphoproliferative Disorders / diagnosis. Methotrexate / adverse effects
  • [MeSH-minor] Aged. Antirheumatic Agents / adverse effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Proliferation. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Female. Herpesvirus 4, Human / immunology. Humans. Male

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19628340.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Merchant SH, Amin MB, Viswanatha DS: Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol; 2006 Jul;126(1):29-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis.
  • The morphologic features and immunophenotype of diagnostic nodal and bone marrow biopsy specimens were reviewed in 29 well-established cases of angioimmunoblastic T-cell lymphoma (AILT).
  • All cases showed a characteristic polymorphous lymphoid and inflammatory cell infiltrate along with stromal-vascular changes.
  • Unique architectural changes, including extranodal extension (83%), follicular dendritic cell proliferation (93%), and a distinctly marginalized distribution of residual B cells (67%) were observed.
  • Subsets of T cells with immunophenotypic abnormalities (CD10 coexpression or loss of pan-T-cell antigens CD3 and CD7) were identified in a majority of cases (96%).
  • Significantly, these morphologic and phenotypic features were seen irrespective of the presence of an overt lymphomatous pattern.
  • Our results indicate that unique morphologic alterations and subsets of phenotypically aberrant T cells are present consistently in nearly all cases of AILT, including morphologically less definitive biopsy specimens.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. DNA, Neoplasm / analysis. Dendritic Cells, Follicular / metabolism. Dendritic Cells, Follicular / pathology. Early Diagnosis. Female. Flow Cytometry. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Polymerase Chain Reaction. T-Lymphocyte Subsets / metabolism. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753608.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


56. Noorali S, Nasir MI, Pervez S: Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients. J Coll Physicians Surg Pak; 2005 Jul;15(7):404-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • OBJECTIVE: To characterize angioimmunoblastic T-cell lymphoma (AILT) on morphological, immunohistochemical and molecular grounds and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • PATIENTS AND METHODS: Over a period of 11 years archival biopsy material of 13 AILT cases (lymph nodes), identified on the basis of histological and immunohistochemical criteria, using REAL and WHO classifications, were retrieved from the files of Department of Pathology.
  • Immunophenotyping was carried out by using CD45 (LCA), two T-cell markers CD45RO (UCHL1; monoclonal) and CD3 (polyclonal).
  • Polymerase chain reaction (PCR) was used to assess T-cell clonality for T-cell receptor (TCR)-b, g and immunoglobulin heavy chain (IgH) for FR2 and FR3 regions using primers recognizing conserved sequences of the variable (V), diversity (D) and joining (J) region segments.
  • Association of EBV in AILT cases was studied by PCR and in situ hybridization (ISH).
  • RESULTS: This study showed AILT to constitute 0.71% of all NHLs (non-Hodgkin's lymphoma) [both T and B].
  • All the 13 cases were largely negative for CD20 (L26), a B-cell marker, except few large scattered cells labelling.
  • PCR technique demonstrated clonal gene rearrangement of the TCR-b, g and IgH regions in 3 (23.1%), 7 (53.8%) and 3 (23.1%) AILT cases, respectively out of 13 cases.
  • Association of EBV was seen in 11 out of 13 cases (84.6%) of AILT by PCR.
  • CONCLUSION: The prevalence of AILT in the Pakistani population is slightly lower compared to other studies and that EBV is an etiological agent in pathogenesis of this disease.
  • [MeSH-major] Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197868.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


57. Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, Rodriguez-Justo M, Plonquet A, Rodriguez-Pinilla SM, Klapper W, Hansmann ML, Pileri SA, Isaacson PG, Stein H, Piris MA, Mason DY, Gaulard P: The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica; 2010 Mar;95(3):432-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.
  • BACKGROUND: T follicular helper (T(FH)) cells reside in the light zone of germinal centers and are considered the cell of origin of angioimmunoblastic T-cell lymphoma.
  • Recently, CXCL13, PD-1 and SAP were described as useful markers for T(FH) cells and angioimmunoblastic T-cell lymphoma but also reported in some peripheral T-cell lymphomas, not otherwise specified.
  • DESIGN AND METHODS: In the present study the expression pattern of ICOS protein was investigated by immunohistochemistry-based techniques in routine sections of normal lymphoid tissues and 633 human lymphomas.
  • In lymphomas, ICOS expression was confined to angioimmunoblastic T-cell lymphoma (85/86), peripheral T-cell lymphomas of follicular variant (18/18) and a proportion of peripheral T-cell lymphomas, not otherwise specified (24/56) that also expressed other T(FH)-associated molecules.
  • CONCLUSIONS: ICOS is a useful molecule for identifying T(FH) cells and its restricted expression to angioimmunoblastic T-cell lymphoma and a proportion of peripheral T-cell lymphomas, not otherwise specified (showing a T(FH)-like profile) suggests its inclusion in the antibody panel for diagnosing T(FH)-derived lymphomas.
  • Our findings provide further evidence that the histological spectrum of T(FH)-derived lymphomas is broader than previously assumed.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / metabolism. Biomarkers, Tumor / metabolism. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Cells, Cultured. Flow Cytometry. Humans. Immunophenotyping. Inducible T-Cell Co-Stimulator Protein. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 2000 Jun 15;42(3):180-7 [10861691.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):753-61 [19329936.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5035-40 [11046032.001]
  • [Cites] Eur J Immunol. 2000 Dec;30(12):3707-17 [11169414.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):97-101 [11343121.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):102-5 [11343122.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):105-9 [11343123.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):573-4 [11429535.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):597-604 [11429543.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):5741-8 [11698447.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Transplantation. 2002 Apr 15;73(7):1027-32 [11965027.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1374-80 [12481020.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):181-93 [12538658.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2310-5 [12594252.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):392-401 [12645936.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):234-43 [12865411.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):544-56 [12876557.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):765-72 [12833154.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1381-8 [12714510.001]
  • [Cites] Curr Opin Immunol. 2004 Jun;16(3):321-7 [15134781.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):263-6 [9930702.001]
  • [Cites] Annu Rev Immunol. 2005;23:515-48 [15771580.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3372-80 [15618467.001]
  • [Cites] Nature. 2005 May 26;435(7041):452-8 [15917799.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):784-91 [16084948.001]
  • [Cites] Cell Mol Immunol. 2004 Feb;1(1):37-42 [16212919.001]
  • [Cites] Leukemia. 2006 Feb;20(2):296-303 [16341050.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):3035-43 [16364514.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):78-87 [16633785.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):802-10 [16819321.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1059-66 [17640856.001]
  • [Cites] Nature. 2007 Nov 8;450(7167):299-303 [18172933.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):774-82 [18178815.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3778-92 [18218851.001]
  • [Cites] Immunity. 2008 Jun;28(6):870-80 [18513999.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1050-8 [18479731.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):439-41 [18729855.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1787-99 [18779728.001]
  • [Cites] Science. 2009 Mar 13;323(5920):1488-92 [19286559.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):682-90 [19295409.001]
  • [CommentIn] Haematologica. 2010 Mar;95(3):356-8 [20207841.001]
  • (PMID = 20207847.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein
  • [Other-IDs] NLM/ PMC2833073
  •  go-up   go-down


58. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol; 2006 Aug;19(8):1101-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified.
  • The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma.
  • Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory.
  • To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia.
  • By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks.
  • Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%).
  • The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology.
  • While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma.
  • In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm.
  • Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chemokines, CXC / metabolism. Germinal Center / metabolism. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chemokine CXCL13. Diagnosis, Differential. Humans. Pseudolymphoma / metabolism. Pseudolymphoma / pathology. Up-Regulation

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2007 Feb;20(2):277. Attygale, Ayoma D [corrected to Attygalle, Ayoma D]
  • (PMID = 16680156.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC
  •  go-up   go-down


59. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC, International Peripheral T-Cell Lymphoma Project: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood; 2010 Feb 4;115(5):1026-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
  • Peripheral T-cell lymphoma (PTCL) is often challenging to diagnose and classify.
  • Gene expression profiling was performed on 144 cases of PTCL and natural killer cell lymphoma and robust molecular classifiers were constructed for angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma.
  • Many of the pathologic features and substantial components of the molecular signature of AITL are contributed by the follicular dendritic cells, B-cell, and other stromal components.
  • The expression of Th17-associated molecules in ALK(+) ALCL was noted and may represent aberrant activation of Th17-cell differentiation by abnormal cytokine secretion.
  • Adult T-cell leukemia/lymphoma has a homogeneous molecular signature demonstrating high expression of human T-lymphotropic virus type 1-induced genes.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2006-10 [14764663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5154-7 [15100251.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):605-13 [15289861.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Nouv Rev Fr Hematol. 1990;32(1):39-41 [2140884.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Feb 1;89(3):948-56 [9028326.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1284-93 [16160469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Jul 1;108(1):218-27 [16527888.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):817-28 [17202343.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):613-24 [17465721.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1382-7 [17693651.001]
  • [Cites] BMC Genomics. 2007;8:230 [17623099.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):151-60 [18071945.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):48-57 [19011627.001]
  • [Cites] Nat Rev Immunol. 2009 Jan;9(1):39-46 [19079134.001]
  • [Cites] Arthritis Rheum. 2009 Mar;60(3):750-9 [19248112.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Curr Hematol Malig Rep. 2006 Jun;1(2):129-36 [20425343.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):525-33 [11169934.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4333-43 [11970975.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16831-6 [11877449.001]
  • [Cites] J Mol Diagn. 2002 Aug;4(3):137-43 [12169674.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 2004 Jan 1;103(1):236-41 [12958063.001]
  • [CommentIn] Blood. 2010 Feb 4;115(5):919-20 [20133472.001]
  • (PMID = 19965671.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE19069
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / CA36727; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / P30 CA036727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2817630
  •  go-up   go-down


60. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA: Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):792-802
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.
  • Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare.
  • Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs.
  • We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Inflammation / immunology. Lymphoma, T-Cell / immunology. Mast Cells / immunology. Th17 Cells / immunology. Tumor Microenvironment

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Annu Rev Immunol. 2008;26:705-39 [18370925.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):478-86 [18483499.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Am J Clin Pathol. 2008 Oct;130(4):613-9 [18794055.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1215-23 [18936782.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71 [18684638.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:272-9 [19074096.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1 Suppl 1:S43-6 [19079228.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1246-54 [19056856.001]
  • [Cites] Haematologica. 2009 Jan;94(1):127-30 [19029148.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):92-107 [19119024.001]
  • [Cites] Immunity. 2009 Mar 20;30(3):324-35 [19303387.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Nat Rev Rheumatol. 2009 Jun;5(6):325-31 [19434074.001]
  • [Cites] Curr Opin Immunol. 2009 Jun;21(3):274-80 [19524429.001]
  • [Cites] Am J Hematol. 2009 Jul;84(7):435-8 [19484731.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5619-22 [19567669.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1141-9 [19470694.001]
  • [Cites] Immunobiology. 2009;214(9-10):835-42 [19628296.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] N Engl J Med. 2009 Aug 27;361(9):888-98 [19710487.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4197-203 [19636021.001]
  • [Cites] J Immunol. 2009 Oct 1;183(7):4169-75 [19767566.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2639-48 [19643985.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2936-44 [19671921.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Nov;72(2):125-43 [19233683.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):79-87 [19740519.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Trends Immunol. 2010 Mar;31(3):97-102 [20149743.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2810-7 [20101023.001]
  • [Cites] Br J Haematol. 2010 Mar;148(5):673-89 [19961485.001]
  • [Cites] J Rheumatol. 2000 Apr;27(4):1087-90 [10782842.001]
  • [Cites] J Pathol. 2003 Feb;199(2):201-7 [12533833.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3037-45 [12626558.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1512-9 [15311211.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1504-8 [8751470.001]
  • [Cites] Acta Haematol. 2005;114(2):108-12 [16103635.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • (PMID = 20595635.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL13; 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-6
  • [Other-IDs] NLM/ PMC2913370
  •  go-up   go-down


61. Munemasa S, Sakai A, Sasaki N, Okikawa Y, Mihara K, Kimura A: [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma]. Rinsho Ketsueki; 2005 Feb;46(2):127-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma].
  • The immunohistochemical and pathologic findings from the biopsy specimens led to the diagnosis of angioimmunoblastic T-cell lymphoma (AILT) with a cluster of CD20-positive cells.
  • These findings indicated a diagnosis of angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma, and that immunodeficiency in AILT led to an expansion of EBV infected B-cells.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunoblastic Lymphadenopathy / complications. Lymphoma, B-Cell / etiology
  • [MeSH-minor] Aged. Gene Rearrangement. Humans. Immunocompromised Host. Immunoglobulin Heavy Chains / genetics. Male. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447706.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


62. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


63. Baseggio L, Berger F, Morel D, Delfau-Larue MH, Goedert G, Salles G, Magaud JP, Felman P: Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia; 2006 Feb;20(2):296-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.
  • In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques.
  • Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis.
  • In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data.
  • Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node.
  • In contrast, in all control samples (100), none CD10-positive T cell was identified.
  • Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Neoplastic Cells, Circulating / immunology. Neoplastic Cells, Circulating / pathology. Neprilysin / biosynthesis. T-Lymphocytes / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341050.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


64. Jones D: Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection. Semin Hematol; 2010 Apr;47 Suppl 1:S1-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection.
  • Many types of peripheral T-cell lymphoma (PTCL) are currently classified by the World Health Organization (WHO) based on their predominant site of organ involvement (eg, intestinal or cutaneous types).
  • However, this approach and traditional staging scores such as the IPI can provide limited prognostic information, especially in those PTCL types where morbidity and mortality are primarily related to immune dysregulation and cytokine syndromes driven by the lymphoma cells.
  • These "immune participatory" PTCLs (including, commonly, angioimmunoblastic T-cell lymphoma and many extranodal types) can therefore have poor outcomes even at low tumor burdens.
  • For these reasons, a classification that includes functional profiling of the lymphoma cells may add valuable prognostic information.
  • Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Cell Differentiation. Humans. Leukemia-Lymphoma, Adult T-Cell / classification. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / classification. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoproliferative Disorders / classification. Lymphoproliferative Disorders / pathology. Prognosis. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359579.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 13
  •  go-up   go-down


65. Basu D, Bundele M: Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):500-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report.
  • Epithelioid cell granuloma occurs in association with many neoplasms including lymphoma.
  • However they have rarely obscured the microscopic features of a lymphoma.
  • We report on a case where a florid epithelioid cell granulomatous reaction caused difficulty in interpretation and delayed the final diagnosis of a case of peripheral T cell lymphoma of the angioimmunoblastic type.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Diagnosis, Differential. Epithelioid Cells / pathology. Granuloma / pathology. Humans. Immunoblastic Lymphadenopathy / pathology. Lymphadenitis / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366110.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


66. Lafaras C, Mandala E, Venizelos I, Valeri R, Barbetakis N, Bischiniotis T: Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma. Onkologie; 2008 Oct;31(10):546-8
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
  • BACKGROUND: Cardiac tamponade (CT) as the primary clinical manifestation of lymphomas is extremely rare.
  • Angioimmunoblastic T-cell lymphoma (AILT) is characterised by systemic disease usually presenting with generalised peripheral lymphadenopathy, hepatosplenomegaly, and bone marrow infiltration.
  • CASE REPORT: We report on a 59-year-old male patient with CT as initial clinical manifestation of AILT.
  • Coexistence with malignant pleural mesothelioma was additionally revealed.
  • Cytologic examination of pericardial fluid presented diffuse lymphoid cells and sporadic malignant mesothelial cells.
  • AILT diagnosis was confirmed by thoracoscopic mediastinal lymph node and bone marrow biopsy.
  • Despite the presence of pleural effusion, the diagnosis of mesothelioma was initially established by cytologic ex-amination of pericardial fluid, due to the patient's critical cardiac condition requiring prompt subxiphoid pericardiocentesis.
  • CONCLUSION: CT as primary clinical manifestation of AILT is very rare.
  • This case reflects the differences in the underlying biology of AILT and consequently the vast spectrum of its clinical presentations.
  • Coexistence of AILT with malignant pleural mesothelioma is also extremely rare.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis. Mesothelioma / complications. Mesothelioma / diagnosis


67. Langer R, Geissinger E, Rüdiger T, von Schilling C, Ott G, Mandl-Weber S, Quintanilla-Martinez L, Fend F: Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone. Am J Surg Pathol; 2010 Sep;34(9):1382-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone.
  • We report a case of primary Epstein Barr virus (EBV) negative peripheral T-cell lymphoma (PTCL) NOS in a 56-year-old female who-after an initially indolent course - simultaneously developed an aggressive, EBV+ cytotoxic large T-cell lymphoma, clonally related to the primary PTCL, and an EBV+, clonal large B-cell lymphoproliferation.
  • The initial, EBV-negative PTCL had shown some features of angioimmunoblastic T-cell lymphoma and had responded well to steroid therapy.
  • Two years later, rapidly fatal, progressive disease with multivisceral involvement developed.
  • Extensive comparative phenotypic and molecular analyses confirmed the presence of an identical CD8+ T-cell clone in the initial EBV-negative PTCL and the EBV+, CD8+ large cell lymphoma at the time of aggressive transformation.
  • These results also justified the retrospective classification of PTCL, NOS for the initial lymphoma.
  • This case shows that secondary EBV infection of an established malignant T-cell clone can occur and may contribute to aggressive transformation of PTCL.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Clone Cells. DNA, Neoplasm / analysis. DNA, Viral / analysis. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Lymph Nodes / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739840.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


68. Yuan X, Chen F, Bi D, Zhao X, He Q, Li Q: [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun;34(6):523-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and diagnosis of 18 patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the clinical and pathologic features of angioimmunoblastic T-cell lymphoma(AITL) and provide evidence for diagnosis.
  • RESULTS: Characteristic features at the presentation of AITL included generalized lymphadenopathy, fever, splenomegaly, and skin rashes with polyclonal hyper-gammaglobulinemia and other hematological abnormalities (such as Coombs-positive hemolytic anemia), which often involved the bone marrow and had well-described histologic features.
  • CONCLUSION: Repeated lymphadenbiopsy is helpful for AITL diagnosis.
  • Routine histological and immunohistochemical examinations (especially including CXCL13) play significant role in the diagnosis and differential diagnosis of AITL.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587435.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13
  •  go-up   go-down


69. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology; 2007 Mar;50(4):498-508
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics.
  • AIMS: To identify distinguishing histological, immunophenotypic and molecular genetic features between angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma (PTL).
  • METHODS: Nodal T-cell lymphomas examined (n =137), included AITL (n = 89), PTL (n = 22), anaplastic large cell lymphoma (n = 16) and 'AITL/PTL indeterminate' (n = 10) with overlapping features between AITL and PTL, showing morphology typical of AITL but lacking follicular dendritic cell expansion.
  • Immunohistochemistry for CD3, CD20, CD21 and CD10, in situ hybridization for Epstein-Barr virus encoded RNA (EBER) and polymerase chain reaction for T-cell and B-cell clonality analysis were performed.
  • Detection of T-cell clonality was significantly higher in AITL (90%) compared with PTLu (59%).
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / pathology. Clone Cells. Diagnosis, Differential. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Neprilysin / metabolism. Polymerase Chain Reaction. RNA, Viral / analysis. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Complement 3d / metabolism. Sensitivity and Specificity. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448026.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


70. Smithberger ES, Rezania D, Chavan RN, Lien MH, Cualing HD, Messina JL: Primary cutaneous angioimmunoblastic T-cell lymphoma histologically mimicking an inflammatory dermatosis. J Drugs Dermatol; 2010 Jul;9(7):851-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous angioimmunoblastic T-cell lymphoma histologically mimicking an inflammatory dermatosis.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a systemic lymphoproliferative disease characterized by a polymorphous neoplastic infiltrate involving lymph nodes as well as extranodal locations, including the skin.
  • Cutaneous involvement is seen in approximately 50 percent of cases and is usually secondary to systemic disease.
  • Patients with cutaneous involvement classically present with a transient morbilliform eruption of the trunk; however, papules, nodules, urticarial plaques and erythroderma have also been reported.
  • [MeSH-major] Dermatitis / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677543.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Woda BA: Hypersensitivity pneumonitis: an immunopathology review. Arch Pathol Lab Med; 2008 Feb;132(2):204-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Hypersensitivity pneumonitis (HSP) is an immunologically mediated alveolar and interstitial lung disease caused by repeated inhalation of organic dusts and some occupational agents.
  • A number of unexplained features of HSP remain, namely (1) why do so few exposed individuals develop clinical HSP, (2) what triggers an acute episode after prolonged periods of previous sensitization, and (3) what leads to disease progression.
  • CONCLUSIONS: Current data suggest that individuals with a T(H)1 dominant response are likely to develop clinical disease.
  • There is also some evidence that genetic factors such as polymorphisms in the major histocompatibility complex, tumor necrosis factor alpha, and tissue inhibitor of metalloproteinase 3 are associated with the development of or resistance to the disease.
  • [MeSH-minor] Genetic Predisposition to Disease. Humans. Killer Cells, Natural / immunology. Lung / immunology. Lung / pathology. T-Lymphocyte Subsets / immunology. Th1 Cells / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251577.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


72. Coca Díaz F, García Alhambra Mde L, Rada Martínez S, Menárguez J, Serra Rexach JA: [Angioimmunoblastic lymphoma in a 73-year-old woman]. Rev Esp Geriatr Gerontol; 2008 Mar-Apr;43(2):117-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic lymphoma in a 73-year-old woman].
  • [Transliterated title] Linfoma angioinmunoblástico en anciana de 73 años.
  • We describe the case of a 73-year-old woman with constitutional disorder and pain in the lower limbs, leading to initial suspicion of multiple myeloma.
  • After a fulminant clinical course for a few days, the patient died, and a postmortem diagnosis of angioimmunoblastic lymphoma was established.
  • We review the main aspects of this highly infrequent disease, the pathogenesis of which remains uncertain.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682123.001).
  • [ISSN] 0211-139X
  • [Journal-full-title] Revista española de geriatría y gerontología
  • [ISO-abbreviation] Rev Esp Geriatr Gerontol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Muenst S, Dirnhofer S, Tzankov A: Distribution of PD-1+ lymphocytes in reactive lymphadenopathies. Pathobiology; 2010;77(1):24-7
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of PD-1+ lymphocytes in reactive lymphadenopathies.
  • It has been proposed that an increase in PD-1+ cells outside GC could indicate pattern I angioimmunoblastic T-cell lymphoma (AITL).
  • METHODS: We studied the distribution of PD-1+ cells in reactive lymphadenopathies (LA), including HIV-associated and dermatopathic LA (n = 5, each), Castleman (n = 3), Kikuchi (n = 2) and Rosai-Dorfman diseases (n = 1), sarcoidoses (n = 7) and follicular hyperplasias (n = 8).
  • RESULTS: The highest concentrations of PD-1+ cells in GC were found in Castleman and Rosai-Dorfman diseases (mean 57 and 50% of total cells, respectively), and the lowest in HIV-associated LA (mean 6%).
  • The highest proportions in paracortices were found in Castleman disease, and in HIV-associated and dermatopathic LA (mean 7, 3 and 2%, respectively).
  • No paracortical PD-1+ cells were found in sarcoidoses and Rosai-Dorfman disease.
  • Since increased numbers of PD-1+ cells outside GC are observed in various LA, this finding might not be entirely specific for pattern I AITL.
  • [MeSH-major] Antigens, CD / immunology. Apoptosis Regulatory Proteins / immunology. Lymphatic Diseases / classification. Lymphatic Diseases / pathology. Lymphocytes / pathology
  • [MeSH-minor] Giant Lymph Node Hyperplasia / pathology. Histiocytosis, Sinus / pathology. Humans. Immunoblastic Lymphadenopathy / pathology. Programmed Cell Death 1 Receptor. Sarcoidosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20185964.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


74. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C: High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol; 2007 Jun;86(6):435-42
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
  • Although the role of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in the treatment of aggressive lymphoma has been established in several large prospective studies, its effectiveness in patients with peripheral T cell lymphoma (PTCL) has not been defined.
  • Twenty patients had PTCL-U (peripheral T cell lymphoma, unspecified), 10 had extranodal natural killer/T cell lymphoma, 5 had anaplastic large cell lymphoma, 3 had angioimmunoblastic T cell lymphoma, 1 had hepatosplenic gammasigma T cell lymphoma, and 1 had disseminated mycosis fungoides.
  • Disease status at transplant was complete response (CR)1 in 3 patients, CR2 or greater in 8, partial remission in 25, and refractory in 4.
  • Ten patients (25%) remain alive without evidence of disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft Survival. Hematopoietic Stem Cell Mobilization / methods. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256144.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


76. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood; 2010 Nov 4;116(18):3418-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
  • To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Killer Cells, Natural / pathology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult


77. Mizobe T, Tsukada J, Higashi T, Iwashige A, Ota T, Kawano I, Kubota A, Matsuura A, Morimoto H, Ogawa R, Toda Y, Tanaka Y: [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia]. Rinsho Ketsueki; 2005 Mar;46(3):211-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia].
  • A 71-year-old woman was admitted in December 2002 because of lymphadenopathy, hepatosplenomegaly and pleural effusion.
  • Bone marrow aspiration showed an almost total absence of erythroblasts and no pathological cell proliferation.
  • The diagnosis of angioimmunoblastic T-cell lymphoma (AILT) was made based on the lymph node histological findings.
  • After combination chemotherapy (THP-COP), remission was achieved in both the pure red cell aplasia (PRCA) and AILT.
  • Remission was also accompanied by normalization of the Coombs tests, suggesting that autoimmune mechanisms in AILT may contribute to the development of PRCA.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Red-Cell Aplasia, Pure / etiology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  • [Number-of-references] 10
  •  go-up   go-down


78. Nakashima M, Suzuki K, Okada M, Takada K, Kobayashi H, Hama Y: Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma. Clin Rheumatol; 2007 Aug;26(8):1362-4
Genetic Alliance. consumer health - Polyarteritis nodosa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma.
  • Polyarteritis nodosa (PN) occasionally develops in association with malignant disorders.
  • A biopsy of the right inguinal lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL).
  • [MeSH-major] Aneurysm, Ruptured / therapy. Embolization, Therapeutic. Hepatic Artery / pathology. Immunoblastic Lymphadenopathy / complications. Polyarteritis Nodosa / complications
  • [MeSH-minor] Aged. Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106619.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


79. Togashi M, Wakui H, Kodama K, Kameoka Y, Komatsuda A, Nimura T, Ichinohasama R, Sawada K: Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association. Clin Exp Nephrol; 2010 Jun;14(3):288-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association.
  • A 21-year-old man with lymphadenopathy and Coombs-positive hemolytic anemia had been treated with steroid maintenance therapy.
  • He developed nephrotic syndrome with size increase of lymphadenopathy.
  • Lymph node examination disclosed angioimmunoblastic T-cell lymphoma (AITL).
  • [MeSH-major] Glomerulonephritis, Membranous / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / diagnosis. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Membranous nephropathy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20177729.001).
  • [ISSN] 1437-7799
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


80. Matsumiya H, Arai A, Nagai A: [A case of angioimmunoblastic T-cell lymphoma with interstitial shadow which disappeared after injection of hydrocortisone]. Nihon Kokyuki Gakkai Zasshi; 2006 Jul;44(7):537-40
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of angioimmunoblastic T-cell lymphoma with interstitial shadow which disappeared after injection of hydrocortisone].
  • A case of angioimmunoblastic T-cell lymphoma (AITL) was reported.
  • Her chest X-ray on admission showed mediastinal and bilateral hilar lymphademopathy (BHL) and interstitial shadows in both lower lung fields.
  • After intravenous injection of 200mg of hydrocortisone for 7 days, the interstitial shadows and BHL disappeared.
  • It was suspected that interstitial shadow was caused by pulmonary infiltration of AITL.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Hydrocortisone / administration & dosage. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / radiography. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886813.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


81. Mori M, Inoue D, Arima H, Takiuchi Y, Nagano S, Kimura T, Shimoji S, Nagai Y, Tabata S, Yanagita S, Matsushita A, Nagai K, Imai Y, Takahashi T: [Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma]. Rinsho Ketsueki; 2010 May;51(5):332-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma].
  • The prognosis of angioimmunoblastic T cell lymphoma (AITL) is poor because of chemotherapy-resistance and the short duration of remission.
  • A patient in whom AITL had relapsed 3 months after high dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) achieved a sustained complete remission (CR) with CyA and underwent allogeneic HSCT.
  • In 2 patients who had failed to respond to conventional chemotherapies, the circulating lymphoma cells rapidly disappeared after the initiation of CyA, and one of these patients demonstrated a durable CR.
  • The remaining one patient with advanced AITL did not respond to CyA and died of disease progression.
  • [MeSH-major] Cyclosporine / administration & dosage. Immunoblastic Lymphadenopathy / drug therapy. Immunosuppressive Agents / administration & dosage. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534954.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


82. Chuang SS, Ichinohasama R, Chu JS, Ohshima K: Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma. Int J Hematol; 2010 May;91(4):687-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma.
  • Angioimmunoblastic lymphoma (AITL) is a nodal peripheral T-cell lymphoma characterized by a proliferation of arborizing vessels and hyperplastic follicular dendritic cells as well as a polymorphous lymphoid infiltrate including neoplastic cells with clear cytoplasm.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by the retrovirus human T-cell leukemia virus type I (HTLV-I), and the neoplastic cells are usually large and pleomorphic.
  • Recently, a rare morphologic variant of ATLL with AITL-like features has been reported.
  • Here, we presented a case of peripheral T-cell lymphoma with morphological features of AITL in Taiwan, a country non-endemic for HTLV, and the patient was seropositive for anti-HTLV antibody, which raised the possibility of ATLL with AITL-like features.
  • Our investigations indicated that in an HTLV-I non-endemic area, a peripheral T-cell lymphoma with typical morphologic and immunophenotypic features of AITL could be confidently diagnosed as AITL even if the patient was seropositive for anti-HTLV antibody.
  • [MeSH-major] HTLV-I Antibodies / blood. HTLV-I Infections / complications. HTLV-I Infections / immunology. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198459.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTLV-I Antibodies
  •  go-up   go-down


83. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Eleven cases where polymerase chain reaction results for T-cell receptor-gamma gene rearrangement were directly compared showed an identical band-size in the initial and follow-up biopsies.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • In 4 cases, a dominant B-cell clone was observed in biopsies lacking evidence of DLBCL.
  • A single case was complicated by EBV-negative DLBCL, whereas another with large cell transformation had a T-cell phenotype.
  • In conclusion, AITL represents a clonal T-cell proliferation with a stable T-cell clone throughout the disease.
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


84. Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1065-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
  • A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998.
  • High-dose etoposide was used for autologous peripheral stem cell mobilization.
  • In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed.
  • Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT).
  • The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT.
  • Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant.
  • It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, Follicular / therapy. Lymphoma, T-Cell / etiology. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440766.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


85. Argov O, Charach G, Weintraub M, Shtabsky A: Angioimmunoblastic T-cell lymphoma presenting as giant kidneys: a case report. J Med Case Rep; 2009;3:9258

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma presenting as giant kidneys: a case report.
  • INTRODUCTION: Angioimmunoblastic T-cell lymphoma is a rare form of tumor of the lymph nodes or lymphoid tissue.
  • In this report we describe an unusual presentation of angioimmunoblastic T-cell lymphoma consisting of giant kidneys with no nephrotic syndrome.
  • The results of the physical examination and laboratory tests raised the possibility of neoplastic disease.
  • The genetic examination revealed T-cell lymphoma.
  • Diagnosis was made by a lymph node biopsy, which shows typical findings of angioimmunoblastic T-cell lymphoma.
  • CONCLUSIONS: Angioimmunoblastic T-cell lymphoma can present with huge kidneys without nephrotic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Ann Hematol. 2004 Nov;83(11):731-2 [15309529.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):455-9 [15034757.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • (PMID = 19918294.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2767156
  •  go-up   go-down


86. Qin Y, Shi YK, He XH, Yang JL, Zhang CG, Zhou SY, Liu XF, Liu P, Yang S, Zhou LQ, Han XH, Yao JR: [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jun;32(6):448-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
  • OBJECTIVE: To retrospectively analyze the clinical features and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).
  • All of the patients received CHOP-like regimens as initial chemotherapy, including 4 once treated with radiotherapy and 1 with high dose therapy followed by autologous stem cell transplantation (HDT-ASCT) as upfront consolidation therapy.
  • B-cell, T-cell and NK-cell subgroup proportions in the peripheral blood were tested by flow cytometry in 6 patients.
  • With the median follow-up of 26 months, the overall 2-year survival and disease free survival (DFS) rates were 62.2% and 44.4%, respectively.
  • In the univariate analysis, only age > 30 years and primary refractory disease adversely affected overall survival (OS); age > 30 years, advanced stage, B symptoms and splenomegaly adversely affected DFS.
  • Flow cytometry of peripheral blood lymphocytes showed that 5 of the 6 tested cases had decreasing proportion of CD3(+)CD4(+) T cells, B cells and NK cells but elevated CD3(+)CD8(+) T cells.
  • Two heavily treated patients achieved partial and complete response by thalidomide therapy, with a progression free survival (PFS) of 2 and 6+ months, respectively.
  • Peripheral blood lymphocytes test indicates that AITL patients suffered from both natural and acquired immune defects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Pneumonia / etiology. Prednisone / therapeutic use. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Thalidomide / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819488.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


87. Krivolapov IuA: [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas]. Arkh Patol; 2005 Mar-Apr;67(2):17-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas].
  • Histopathologic features of immunohistochemically confirmed 37 nodal peripheral T-cell lymphomas are described.
  • Unspecified and 10 angioimmunoblastic T-cell lymphomas were analyzed.
  • The most demonstrative histological features of both types of lymphomas were spectrum of small, medium and large lymphoid cells, lymphoid cells with irregular nuclei, presence of clusters of clear cells, arborizing endothelial venules, increased number of histiocytes, eosinophils and plasma cells.
  • Delineation between peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-cell lymphoma needs evaluation of follicular dendritic cell pattern.
  • The results suggest that detection of histopathologic features typical for peripheral T-cell lymphomas gives an opportunity to compose optimal panel for immunotyping which is absolutely necessary.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938113.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


88. Fujiwara SI, Yamashita Y, Nakamura N, Choi YL, Ueno T, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Abe M, Ozawa K, Mano H: High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia; 2008 Oct;22(10):1891-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays.
  • Angioimmunoblastic T-cell lymphoma (AILT) and peripheral T-cell lymphoma, unspecified (PTCL-u) are relatively frequent subtypes of T- or natural killer cell lymphoma.
  • To characterize the structural anomalies of chromosomes associated with these disorders, we here determined chromosome copy number alterations (CNAs) and loss of heterozygosity (LOH) at >55,000 single nucleotide polymorphism loci for clinical specimens of AILT (n=40) or PTCL-u (n=33).
  • AILT- or PTCL-u-specific CNAs or LOH were also identified at 21 regions, some spanning only a few hundred base pairs.
  • Our data indicate that AILT and PTCL-u consist of heterogeneous subgroups with distinct transforming genetic alterations.
  • [MeSH-major] Chromosome Aberrations. Loss of Heterozygosity. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633432.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / IKZF2 protein, human; 0 / MYCBP protein, human; 0 / Transcription Factors; 148971-36-2 / Ikaros Transcription Factor; EC 3.4.24.11 / Neprilysin; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


89. Tomita N, Motomura S, Hyo R, Takasaki H, Takemura S, Taguchi J, Fujisawa S, Ogawa K, Ishigatsubo Y, Takeuchi K: Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Cancer; 2007 Mar 15;109(6):1146-51
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
  • BACKGROUND: Peripheral T-cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis.
  • In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B-cell lymphoma (DLBCL).
  • METHODS: The authors compared the characteristics and outcomes of 59 patients with PTCLs, including 33 angioimmunoblastic T-cell lymphomas and 26 unspecified peripheral T-cell lymphomas, with the characteristics and outcomes of 193 patients with DLBCLs who were treated in the era before rituximab.
  • The 5-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates were 31%, 26%, and 47%, respectively, in patients with PTCLs and 59%, 55%, and 73%, respectively, in patients with DLBCL (P = .001, P < .001, and P = .003, respectively).
  • T-cell phenotype itself did not appear to have a significant impact on either response or survival.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / mortality


90. Hirose Y, Masaki Y, Sawaki T, Shimoyama K, Karasawa H, Kawabata H, Fukushima T, Ogawa N, Wano Y, Umehara H: Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. Eur J Haematol; 2006 Feb;76(2):109-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan.
  • The association of Epstein-Barr virus (EBV) with human immunodeficiency virus-negative T-cell lymphoma was examined in 68 patients using the polymerase chain reaction (PCR) with DNA obtained from formalin-fixed paraffin-embedded tissues and an in situ hybridization technique.
  • EBV-encoded RNA (EBER) was detected in 43 of 68 cases (63%) of peripheral T-cell lymphoma: in 100% (11 of 11 cases) of NK/T-cell lymphomas, 70% (14 of 20 cases) of angioimmunoblastic T-cell lymphomas (AILT) and 49% (18 of 37 cases) of other types of peripheral T-cell lymphoma.
  • The 5-yr survival rate was 28% for peripheral T-cell lymphomas overall, 0% for NK/T-cell lymphomas, 38% for AILTs and 28% for other types of peripheral T-cell lymphoma.
  • The difference in the overall survival rate between NK/T-cell lymphoma and non-NK/T-cell lymphoma was significant (P = 0.0498 by Log-rank test).
  • Among peripheral T-cell lymphoma patients overall, the group severely infected with EBV (EBER-ISH ++) had a lower 5-yr survival rate (8%) than the group slightly (EBER-ISH +) or not infected (38%; P = 0.0013).
  • [MeSH-major] HIV Seronegativity. Herpesvirus 4, Human / isolation & purification. Lymphoma, T-Cell / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405431.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


91. Viallard JF, Lazaro E, Lafon ME, Pellegrin JL: Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1659-62
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • [MeSH-major] Cytosine / analogs & derivatives. Immunoblastic Lymphadenopathy / complications. Leukoencephalopathy, Progressive Multifocal / drug therapy. Lymphoma, T-Cell / complications. Organophosphonates / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334909.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


92. de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P: Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol; 2009 Nov;72(2):125-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of T-cell lymphomas.
  • T-cell neoplasms encompass a heterogeneous group of relatively rare disease entities.
  • This review, focused on lymphoblastic tumors (T-ALL/LBL) and nodal-based peripheral T-cell lymphomas (PTCL), summarizes recent advances in the molecular characterization of these diseases.
  • Angioimmunoblastic T-cell lymphoma (AITL), one of the most common PTCL entities, comprises neoplastic cells with a molecular signature similar to normal follicular helper T cells, and this cellular derivation might account for several of the peculiar aspects of this disease.
  • Except in ALK-positive anaplastic large cell lymphoma, defined by ALK gene fusions, chromosomal translocations are otherwise rare in PTCLs, but some recurrent rearrangements might be associated with distinct lymphoma subtypes.
  • In PTCL, not otherwise specified (PTCL, NOS), novel molecular biomarkers of potential therapeutic interest have been recently identified.
  • [MeSH-major] Biomarkers, Tumor / genetics. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233683.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 111
  •  go-up   go-down


93. Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC: Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer; 2007 Jan;46(1):37-44
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a histopathologically well-defined entity.
  • However, despite a number of cytogenetic studies, the genetic basis of this lymphoma entity is not clear.
  • Moreover, there is an overlap to some cases of peripheral T-cell lymphoma unspecified (PTCL-u) in respect to morphological and genetic features.
  • We used array-based comparative genomic hybridization (CGH) to study genetic imbalances in 39 AILT and 20 PTCL-u.
  • Array-based CGH revealed complex genetic imbalances in both AILT and PTCL-u.
  • Chromosomal imbalances were more frequent in PTCL-u than in AILT and gains exceeded the losses.
  • The most recurrent changes in AILT were gains of 22q, 19, and 11p11-q14 (11q13) and losses of 13q.
  • Interestingly, gains of 4q (4q28-q31 and 4q34-qtel), 8q24, and 17 were significantly more frequent in PTCL-u than in AILT.
  • Moreover, we could identify a recurrent gain of 11q13 in both AILT and PTCL-u, which has previously not been described in AILT.
  • Trisomies 3 and 5, which have been described as typical aberrations in AILT, were identified only in a small number of cases.
  • In conclusion, CGH revealed common genetic events in peripheral T-cell lymphomas as well as peculiar differences between AILT and PTCL-u.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044049.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Protein kinase C (PKC) beta is an important regulator of lymphoid survival and its expression has been shown to be altered in lymphomas.
  • The aim was to determine the expression of PKC beta(2) in various subtypes of lymphoproliferative diseases by immunohistochemistry.
  • METHODS AND RESULTS: One hundred and forty archival samples representing various subtypes of lymphoproliferative diseases were analysed.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • In follicular lymphomas, the follicular lymphomatous areas were constantly labelled, whereas residual germinal centres remained negative.
  • Most angioimmunoblastic T-cell lymphomas, lymphoblastic T-cell lymphomas and marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas were labelled with anti-PKC betaII antibody, but the pattern of expression was more heterogeneous in these subtypes.
  • A minority of diffuse large B-cell lymphomas were stained and most plasma cell malignancies were negative.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • CONCLUSIONS: PKC beta(2) expression varies significantly among lymphoproliferative diseases.
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


95. Zhao WL, Liu YY, Plassa F, Jin XL, Wang L, Janin A, Shen ZX: [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):664-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the vascular endothelial growth factor-C (VEGF-C) expression and its clinical significance in malignant lymphoma.
  • METHODS: Lymphoma cells were isolated by laser microdissection.
  • VEGF-C expression in lymphoma tissue and microdissected lymphoma cells was measured by realtime quantitative PCR.
  • RESULTS: Comparing with that in 8 patients with reactive lymphocyte hyperplasia, VEGF-C was overexpressed in angioimmunoblastic T-cell lymphoma, both in lymphoma tissue (n = 18, P = 0.0020) and in microdissected lymphoma cells (n = 10, P < 0.0001).
  • CONCLUSION: The value of VEGF-C expression might be a biomarker of disease progression in angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Vascular Endothelial Growth Factor C / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399170.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


96. Greer JP: Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program; 2006;:331-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of peripheral T/NK neoplasms.
  • The mature T/natural killer (NK) lymphoma/leukemias represent 5-15% of all non-Hodgkin lymphoma.
  • These diseases have a geographic variation, with more nodal disease in North America and Europe, including peripheral T cell lymphomas, unspecified, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma; and more extranodal disease in Asia due to Epstein-Barr virus-related nasal NK/T lymphoma and human T-cell leukemia virus (HTLV)-1-associated adult T cell leukemia/lymphoma.
  • The prognosis in most peripheral T/NK neoplasms is poor, with 5-year survival less than 30%.
  • Progress has been slow due to the rarity of the diseases, geographic variation, relative chemoresistance, and lack of randomized trials.
  • In this review, topics include the question of CHOP as standard therapy, prognostic factors, disease-adapted therapy, novel approaches, monoclonal antibody therapy, and stem cell transplantation.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124080.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


97. Balagué O, Martínez A, Colomo L, Roselló E, Garcia A, Martínez-Bernal M, Palacín A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E: Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol; 2007 Sep;31(9):1310-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
  • Clonal B-cell populations have been described in peripheral T-cell lymphomas (PTCL) as secondary Epstein-Barr virus (EBV) driven B-cell expansions that may evolve to an overt B-cell lymphoma.
  • EBV-negative B-cell proliferations associated with T-cell lymphomas are uncommon and not well characterized.
  • We studied 15 patients who developed an EBV-negative B-cell proliferation or malignant lymphoma associated with PTCL.
  • The T-cell tumors were 8 PTCL, not otherwise specified, 4 angioimmunoblastic T-cell lymphomas, and 3 cutaneous PTCL.
  • The B-cell component was intermingled with the PTCL in all patients and it was classified as clonal/monotypic plasma cell proliferation in 8 lesions, clonal/monotypic large B-cell proliferation in 4 patients, and B-cell lymphoma with plasmacytic/plasmablastic differentiation in 3 patients.
  • Two patients had 2 clonally unrelated plasma cell proliferations associated with the same PTCL.
  • Clonal IgH and T-cell receptor rearrangements were detected in 11/12 and 11/13 cases examined, respectively.
  • Sequential samples in 7 patients showed persistence of the PTCL and the B-cell component in 4, the PTCL without the B-cell lymphoma in 2, and progression of the B-cell neoplasm in 1.
  • In conclusion, EBV-negative clonal or mononotypic B-cell proliferations in patients with PTCL present with a spectrum of lesions ranging from plasma cell proliferations to overt lymphomas with plasmacytic/plasmablastic features.
  • [MeSH-major] Cell Proliferation. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adolescent. Aged. Aged, 80 and over. Cell Differentiation. Clone Cells / pathology. Clone Cells / virology. Cytomegalovirus. Female. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 8, Human. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721185.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Al-Anazi KA, Aljurf MD, Al-Mohareb FI, Al-Dabal L, Zaitoni M, Halim M: Successful management of invasive pulmonary nocardiosis and aspergillosis in a patient with T-cell lymphoma: a case report. Clin Med Case Rep; 2008;1:65-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of invasive pulmonary nocardiosis and aspergillosis in a patient with T-cell lymphoma: a case report.
  • In patients with malignant hematological disorders receiving immunosuppressive therapy, invasive pulmonary infections are serious complications that are associated with high morbidity and mortality.
  • Reported here is an old man who was diagnosed to have angioimmunoblastic T-cell lymphoma at King Faisal Specialist Hospital and Research Centre in Riyadh in December 2004.
  • The lymphoma was treated with various immunosuppressive agents including alemtuzumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24179349.001).
  • [ISSN] 1178-6450
  • [Journal-full-title] Clinical medicine. Case reports
  • [ISO-abbreviation] Clin Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3785346
  • [Keywords] NOTNLM ; Aspergillus niger / Nocardia asteroides / angioimmunoblastic T-cell lymphoma / invasive pulmonary infections
  •  go-up   go-down


99. Tzankov AS, Went PT, Münst S, Papadopoulos T, Jundt G, Dirnhofer SR: Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol; 2007 Jun;20(6):632-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.
  • Lineage determination in lymphomas is based on the assessment of lineage-specific markers, such as the B-cell-specific activator protein of the paired box family (BSAP, PAX-5) for the B-cell lineage.
  • BSAP is thought to be expressed exclusively in B cells from the pro-B- to the mature B-cell stage and then silenced in plasma cells.
  • BSAP has oncogenic potential and experimental evidence shows that the T-cell lineage is prone to this effect.
  • Herein, we report on a BSAP-positive peripheral T-cell lymphoma with monoclonal T-cell receptor gamma-gene rearrangement.
  • To assess the relative frequency of BSAP expression in mature T-cell lymphomas, we constructed and examined a tissue microarray consisting of 43 angioimmunoblastic T-cell lymphomas and peripheral T-cell lymphomas and detected no additional BSAP-positive cases.
  • To conclude, BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo.
  • It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / biosynthesis. Cell Lineage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymphoma, T-Cell, Peripheral / metabolism. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431414.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


100. Qubaja M, Audouin J, Moulin JC, Molina TJ, Le Tourneau A, Gaulard P, Straub P, Audhuy B, Diebold J: Nodal follicular helper T-cell lymphoma may present with different patterns. A case report. Hum Pathol; 2009 Feb;40(2):264-9
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal follicular helper T-cell lymphoma may present with different patterns. A case report.
  • We report the case of a 62-year-old patient presenting with 3 different patterns of follicular helper T-cell lymphoma.
  • The patient initially presented with angioimmunoblastic T-cell lymphoma.
  • A nodal relapse in the form of follicular T-cell lymphoma with a progressively transformed germinal center pattern occurred 8 years later.
  • Two years later, this was followed by another relapse presenting as a predominantly large-cell peripheral T-cell lymphoma, unspecified.
  • The immunophenotype showed a progressive increase in the proportion of cells expressing CD10, bcl-6, CXCL13, and programmed death-1 from the first to the last lymphoma.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760445.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement